Unnamed: 0,title,date,stock,sentiment
172288.0,"The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage",2020-06-07 13:43:00-04:00,BLUE,neutral
172289.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to $73",2020-05-28 08:05:00-04:00,BLUE,neutral
172290.0,"SVB Leerink Maintains Outperform on bluebird bio, Raises Price Target to $129",2020-05-28 06:55:00-04:00,BLUE,neutral
172291.0,Bristol-Myers Analyst Says 'Big 7' Pipeline Assets Hold $15B In Peak Sales Potential,2020-05-27 11:45:00-04:00,BLUE,positive
172292.0,"Shares of several healthcare companies are trading higher in sympathy with the overall market amid strength in oil, strong earnings from Lowe's and optimism towards a US economic rebound.",2020-05-20 11:19:00-04:00,BLUE,positive
172293.0,"The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces $1.34B Common Stock Offering",2020-05-19 08:24:00-04:00,BLUE,positive
172294.0,Bluebird Bio shares are trading lower after the company announced a $400 million common stock offering.,2020-05-18 07:19:00-04:00,BLUE,neutral
172295.0,Bluebird Bio Announces $400M Common Stock Offering,2020-05-18 07:14:00-04:00,BLUE,neutral
172296.0,"bluebird bio To Present Data From Gene, Cell Therapy Programs At European Hematology Association Annual Congress On Jun. 12",2020-05-14 09:11:00-04:00,BLUE,neutral
172297.0,"Bristol Myers, bluebird bio Will Present Updated Results From Pivotal KarMMa Study Of Ide-cel In Relapsed and Refractory Multiple Myeloma Patients at ASCO On May 29",2020-05-13 17:03:00-04:00,BLUE,neutral
172298.0,"The Daily Biotech Pulse: Gilead Signs Manufacturing Deal For Remdesivir, Bristol-Myers Gets Refuse-To-File Letter",2020-05-13 07:40:00-04:00,BLUE,neutral
172299.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-05-13 07:33:00-04:00,BLUE,neutral
172300.0,"Bluebird Bio shares are trading lower after the company announced upon its preliminary review, the FDA determined that the chemistry, manufacturing and control module of the BLA for Idecabtagene Vicleucel requires further detail to complete the review.",2020-05-13 07:21:00-04:00,BLUE,positive
172301.0,"Bristol Myers Squibb And  bluebird bio Say Upon Preliminary Review, FDA Determined That The Chemistry, Manufacturing And Control Module Of The BLA For Idecabtagene Vicleucel Requires Further Detail To Complete The Review",2020-05-13 07:00:00-04:00,BLUE,positive
172302.0,"RBC Capital Initiates Coverage On bluebird bio with Outperform Rating, Announces Price Target of $100",2020-05-13 05:05:00-04:00,BLUE,neutral
172303.0,"BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to $112",2020-05-12 10:54:00-04:00,BLUE,neutral
172304.0,Bluebird Bio shares are trading higher after the company reported better-than-expected Q1 EPS results. The company also announced it amended its existing co-development agreement with Bristol Myers Squibb. Bristol Myers Squibb will buy out its obligation to pay future ex-U.S. milestones and royalty payments for $200 million.,2020-05-11 09:03:00-04:00,BLUE,positive
172305.0,Bluebird Bio Announces Amended BCMA CAR-T Collaboration Agreement; Bristol Myers Squibb To Buy Out Its Ex-US Milestone And Royalty Obligations To Bluebird Bio For $200 Million,2020-05-11 07:44:00-04:00,BLUE,positive
172306.0,Hitachi Chemical Advanced Therapeutics Solutions And Apceth Biopharma Enter Into Strategic Clinical And Commercial Manufacturing Agreements With Bluebird Bio,2020-05-11 07:26:00-04:00,BLUE,positive
172307.0,bluebird bio Q1 EPS $(3.640) Beats $(4.010) Estimate,2020-05-11 07:25:00-04:00,BLUE,neutral
172308.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,BLUE,neutral
172309.0,bluebird bio Reports Updated Results From Pivotal Phase 2 KarMMa Study At ASCO 2020 Virtual Program,2020-05-08 07:31:00-04:00,BLUE,neutral
172310.0,"Shares of several healthcare companies are trading higher amid continued economic optimism as some US states ease lockdown restrictions. While jobless claims came in worse than estimates, figures were lower than in prior weeks.",2020-05-07 11:25:00-04:00,BLUE,positive
172311.0,Shares of several healthcare companies are trading lower on market weakness as investor uncertainty grows following quarterly earnings results from multiple companies.,2020-05-01 09:30:00-04:00,BLUE,negative
172312.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $69",2020-04-15 08:58:00-04:00,BLUE,negative
172313.0,Shares of several healthcare companies are trading higher amid overall market strength after the US Federal Reserve announced a further $2.3 trillion in financing programs to support the economy. Other potential positive sector catalysts include demand for therapies and medical supplies amid the coronavirus pandemic and US Senator Sanders exiting the Presidential race.,2020-04-09 09:58:00-04:00,BLUE,positive
172314.0,Bristol Myers Squibb And Bluebird Bio Announce Submission Of Biologics License Application For Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel To FDA,2020-03-31 07:00:00-04:00,BLUE,neutral
172315.0,"Stifel Upgrades bluebird bio to Buy, Lowers Price Target to $70",2020-03-27 04:57:00-04:00,BLUE,negative
172316.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,BLUE,positive
172317.0,Shares of several companies in the healthcare space are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.,2020-03-16 10:18:00-04:00,BLUE,negative
172318.0,Stocks That Hit 52-Week Lows On Friday,2020-03-13 11:13:00-04:00,BLUE,negative
172319.0,Stocks That Hit 52-Week Lows On Thursday,2020-03-12 12:10:00-04:00,BLUE,negative
172320.0,"The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment",2020-03-11 08:03:00-04:00,BLUE,positive
172321.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,BLUE,negative
172322.0,Stocks That Hit 52-Week Lows On Friday,2020-02-28 10:16:00-05:00,BLUE,negative
172323.0,Shares of several healthcare companies are trading lower as the global coronavirus spread continues to cause equities across sectors to sell off amid worsened economic outlook.,2020-02-28 09:06:00-05:00,BLUE,negative
172324.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,BLUE,neutral
172325.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,BLUE,negative
172326.0,Shares of several healthcare companies are trading lower as growing coronavirus fears hamper economic outlook.,2020-02-27 09:28:00-05:00,BLUE,negative
172327.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $92",2020-02-26 08:24:00-05:00,BLUE,negative
172328.0,78 Biggest Movers From Yesterday,2020-02-20 05:16:00-05:00,BLUE,neutral
172329.0,Raymond James Downgrades Bluebird Bio From Strong Buy To Market Perform,2020-02-19 17:04:00-05:00,BLUE,positive
172330.0,51 Stocks Moving In Wednesday's Mid-Day Session,2020-02-19 12:18:00-05:00,BLUE,neutral
172331.0,Bluebird Bio shares are trading lower after the company reported Q4 EPS and sales results down from last year.,2020-02-19 09:47:00-05:00,BLUE,neutral
172332.0,"Stifel Nicolaus Maintains Hold on bluebird bio, Lowers Price Target to $94",2020-02-19 08:49:00-05:00,BLUE,negative
172333.0,"The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA",2020-02-19 07:21:00-05:00,BLUE,negative
172334.0,"bluebird bio Q4 EPS $(4.04) Down From $(2.72) YoY, Sales $9.997M Down From $19.243M YoY",2020-02-18 16:08:00-05:00,BLUE,neutral
172335.0,bluebird bio Q4 Sales $9.997M Down From $19.243M YoY,2020-02-18 16:06:00-05:00,BLUE,neutral
172336.0,85 Biggest Movers From Yesterday,2020-02-04 04:56:00-05:00,BLUE,neutral
172337.0,61 Stocks Moving In Monday's Mid-Day Session,2020-02-03 12:25:00-05:00,BLUE,neutral
172338.0,"Benzinga's Top Upgrades, Downgrades For February 3, 2020",2020-02-03 09:55:00-05:00,BLUE,positive
172339.0,Bluebird Bio shares are trading higher after Evercore ISI upgraded the stock from In-Line to Outperform and raised the price target from $86 to $100.,2020-02-03 09:49:00-05:00,BLUE,positive
172340.0,10 Biggest Price Target Changes For Monday,2020-02-03 08:23:00-05:00,BLUE,neutral
172341.0,"Evercore ISI Group Upgrades bluebird bio to Outperform, Raises Price Target to $100",2020-02-03 06:34:00-05:00,BLUE,neutral
172342.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,BLUE,neutral
172343.0,Bluebird Bio shares are trading higher after the company announced the launch of ZYNTEGLO gene therapy in Germany for patients with transfusion-dependent β-thalassemia who do not have β0/β0 genotype.,2020-01-14 11:47:00-05:00,BLUE,positive
172344.0,bluebird bio Announces Launch in Germany of ZYNTEGLO Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype,2020-01-13 05:15:00-05:00,BLUE,neutral
172345.0,Bluebird Bio shares are trading lower. Not seeing any news to justify the price action.,2019-12-26 13:20:00-05:00,BLUE,neutral
172346.0,Bluebird Bio shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a price target of $135 per share.,2019-12-13 14:24:00-05:00,BLUE,positive
172347.0,"Oppenheimer Upgrades bluebird bio to Outperform, Announces $135 Price Target",2019-12-13 06:24:00-05:00,BLUE,neutral
172348.0,66 Biggest Movers From Yesterday,2019-12-11 04:52:00-05:00,BLUE,neutral
172349.0,Bluebird Bio shares are trading higher on updated results from its Phase 1 trial evaluating its CAR-T candidate bb21217.,2019-12-10 10:39:00-05:00,BLUE,positive
172350.0,"The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares",2019-12-10 07:56:00-05:00,BLUE,positive
172351.0,bluebird bio Highlights Presentation Of New Data Demonstrating Long-Term Transfusion Independence And Safety For LentiGlobin Gene Therapy For β-thalassemia At 61st ASH Annual Meeting And Exposition,2019-12-09 16:33:00-05:00,BLUE,positive
172352.0,"Wells Fargo Maintains Overweight on bluebird bio, Lowers Price Target to $160",2019-12-09 08:53:00-05:00,BLUE,negative
172353.0,38 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-12-09 08:26:00-05:00,BLUE,neutral
172354.0,20 Stocks Moving In Monday's Pre-Market Session,2019-12-09 07:49:00-05:00,BLUE,neutral
172355.0,bluebird bio Presents New Data from Ongoing Phase 1/2 HGB-206 Study of LentiGlobin Gene Therapy for Sickle Cell Disease at ASH 2019,2019-12-07 14:22:00-05:00,BLUE,neutral
172356.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,BLUE,positive
172357.0,"Bristol-Myers, bluebird bio Report Top-Line Results From Phase 2 KarMMa Study Of Ide-cel: Met Primary, Key Secondary Endpoints",2019-12-06 16:18:00-05:00,BLUE,neutral
172358.0,"The Week Ahead In Biotech: ASH 2019 Gets Underway, Biogen's Aducanumab Data And More",2019-12-01 09:30:00-05:00,BLUE,neutral
172359.0,"UPDATE: SVB Leerink Upgrades bluebird bio to Outperform, Reiterates $119 Target Notes Co. 'is trading just below our zero B-cell maturation antigen (BCMA) value estimate of $77/share – setting up an attractive risk/reward into BCMA data'",2019-11-26 11:51:00-05:00,BLUE,positive
172360.0,"Benzinga's Top Upgrades, Downgrades For November 26, 2019",2019-11-26 09:59:00-05:00,BLUE,positive
172361.0,Bluebird Bio shares are trading higher after SVB Leerink upgraded the stock from Market Perform to Outperform and announced a price target of $119 per share.,2019-11-26 09:10:00-05:00,BLUE,positive
172362.0,"SVB Leerink Upgrades bluebird bio to Outperform, Announces $119 Price Target",2019-11-26 07:35:00-05:00,BLUE,neutral
172363.0,"Benzinga's Top Upgrades, Downgrades For November 19, 2019",2019-11-19 09:57:00-05:00,BLUE,positive
172364.0,"Evercore ISI Group Downgrades bluebird bio to In-Line, Announces $86 Price Target",2019-11-19 06:57:00-05:00,BLUE,neutral
172365.0,Bluebird Bio And Forty Seven Announce A Research Collaboration To Study An All Antibody Conditioning Regimen For Use In Combination With Autologous Lentiviral Vector Hematopoietic Stem Cell Gene Therapy,2019-11-12 07:53:00-05:00,BLUE,neutral
172366.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,BLUE,neutral
172367.0,Stocks That Hit 52-Week Lows On Monday,2019-11-11 10:45:00-05:00,BLUE,negative
172368.0,Stocks That Hit 52-Week Lows On Friday,2019-11-08 11:41:00-05:00,BLUE,negative
172369.0,"The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut",2019-11-08 08:14:00-05:00,BLUE,neutral
172370.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,BLUE,negative
172371.0,"Benzinga's Top Upgrades, Downgrades For November 4, 2019",2019-11-04 09:56:00-05:00,BLUE,positive
172372.0,Wedbush Upgrades bluebird bio to Outperform,2019-11-04 06:46:00-05:00,BLUE,neutral
172373.0,"Piper Jaffray Maintains Neutral on bluebird bio, Lowers Price Target to $85",2019-11-01 10:28:00-04:00,BLUE,negative
172374.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $100",2019-11-01 08:20:00-04:00,BLUE,negative
172375.0,"The Daily Biotech Pulse: Amgen Takes 20.5% Stake In BeiGene, Paratek's Mixed Clinical Readout, CareDx Slips On Guidance",2019-11-01 07:38:00-04:00,BLUE,neutral
172376.0,Bluebird Bio shares are trading lower after the company reported Q3 EPS and sales results down from last year.,2019-10-31 16:46:00-04:00,BLUE,neutral
172377.0,"bluebird bio Q3 EPS $(3.73) Down From $(2.73) YoY, Sales $8.91M Down From $11.528M YoY",2019-10-31 16:10:00-04:00,BLUE,neutral
172378.0,Stocks That Hit 52-Week Lows On Friday,2019-10-25 12:49:00-04:00,BLUE,negative
172379.0,"The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug",2019-10-25 07:12:00-04:00,BLUE,positive
172380.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-24 10:22:00-04:00,BLUE,negative
172381.0,European Medicines Agency Approves Refined Commercial Manufacturing Specifications For ZYNTEGLO,2019-10-22 07:45:00-04:00,BLUE,positive
172382.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $104",2019-10-11 08:48:00-04:00,BLUE,negative
172383.0,"The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering",2019-10-04 07:32:00-04:00,BLUE,negative
172384.0,Stocks That Hit 52-Week Lows On Thursday,2019-10-03 13:03:00-04:00,BLUE,negative
172385.0,"The Daily Biotech Pulse: IPOs, Puma's Breast Cancer Drug Gets Label Expansion, Buyout Offer For Organovo",2019-10-03 07:34:00-04:00,BLUE,negative
172386.0,Stocks That Hit 52-Week Lows On Wednesday,2019-10-02 10:55:00-04:00,BLUE,negative
172387.0,"The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data",2019-10-02 07:17:00-04:00,BLUE,positive
172388.0,Stocks That Hit 52-Week Lows On Tuesday,2019-10-01 14:35:00-04:00,BLUE,negative
172389.0,"Stifel Bullish On Iovance And Fate Therapeutics, Neutral On Bluebird Bio",2019-10-01 13:48:00-04:00,BLUE,neutral
172390.0,"UPDATE: Stifel Initiates bluebird bio With Hold, $109 Target As Firm Thinks 'the launch of their lead product Zynteglo will be slow, and there's risk this could lag consensus expectations (informed by a payer survey)'",2019-10-01 10:53:00-04:00,BLUE,negative
172391.0,"Benzinga's Top Upgrades, Downgrades For October 1, 2019",2019-10-01 09:46:00-04:00,BLUE,positive
172392.0,"Stifel Initiates Coverage On bluebird bio with Hold Rating, Announces $109 Price Target",2019-10-01 07:02:00-04:00,BLUE,neutral
172393.0,bluebird bio Highlights Presentation Of Updated Data From Phase 2/3 Study Of Lenti-D Gene Therapy For Cerebral Adrenoleukodystrophy At European Pediatric Neurology Society Congress,2019-09-18 09:26:00-04:00,BLUE,neutral
172394.0,"The Daily Biotech Pulse: NewLink Genetics Rallies, Breakthrough Designation For Roche, IGM Biosciences Debuts",2019-09-18 07:39:00-04:00,BLUE,neutral
172395.0,"The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck",2019-09-15 11:18:00-04:00,BLUE,positive
172396.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,BLUE,positive
172397.0,"Benzinga's Top Upgrades, Downgrades For August 12, 2019",2019-08-12 09:44:00-04:00,BLUE,positive
172398.0,William Blair Downgrades bluebird bio to Market Perform,2019-08-12 07:06:00-04:00,BLUE,neutral
172399.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $136",2019-08-06 09:23:00-04:00,BLUE,negative
172400.0,"bluebird bio Q2 EPS $(3.55) Misses $(3.06) Estimate, Sales $13.3M Beat $10.89M Estimate",2019-08-01 16:38:00-04:00,BLUE,negative
172401.0,35 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-07-25 05:55:00-04:00,BLUE,neutral
172402.0,"Maxim Group Upgrades bluebird bio to Buy, Announces $160 Price Target",2019-06-18 08:07:00-04:00,BLUE,neutral
172403.0,"BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to $163",2019-06-17 09:09:00-04:00,BLUE,negative
172404.0,Consider These New ETFs In A Megatrend Search,2019-06-14 15:37:00-04:00,BLUE,neutral
172405.0,Bluebird Bio shares are trading lower after the company presented data for its LentiGlobin gene therapy for sickle cell disease.,2019-06-14 14:23:00-04:00,BLUE,neutral
172406.0,"The Daily Biotech Pulse:  Hematology And Rheumatology Conference Presentations Take The Spotlight, Eton In-Licenses Epilepsy Drug NDA",2019-06-14 08:47:00-04:00,BLUE,neutral
172407.0,bluebird bio Presents New Data for LentiGlobin Gene Therapy for Sickle Cell Disease at #EHA19,2019-06-14 05:48:00-04:00,BLUE,neutral
172408.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts",2019-06-08 16:09:00-04:00,BLUE,neutral
172409.0,Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.,2019-06-04 13:07:00-04:00,BLUE,positive
172410.0,Bluebird Bio Announces EU Conditional Marketing Authorization For ZYNTEGLO Gene Therapy For Patients 12 Years And Older With Transfusion-Dependent β-Thalassemia Who Do Not Have β0/β0 Genotype,2019-06-03 09:25:00-04:00,BLUE,neutral
172411.0,"Jim Cramer Weighs In On Anadarko, Micron And More",2019-05-30 07:28:00-04:00,BLUE,neutral
172412.0,"bluebird bio To Present New Data From Studies Of LentiGlobin For Transfusion-Dependent β-thalassemia, LentiGlobin Gene Therapy for Sickle Cell Disease at the 24th EHA Congress",2019-05-16 09:30:00-04:00,BLUE,neutral
172413.0,"Bluebird Bio's Near-Term Product Launches Pose Risks, Wedbush Says In Downgrade",2019-05-15 14:10:00-04:00,BLUE,negative
172414.0,10 Biggest Price Target Changes For Wednesday,2019-05-15 09:38:00-04:00,BLUE,neutral
172415.0,"Benzinga's Top Upgrades, Downgrades For May 15, 2019",2019-05-15 09:11:00-04:00,BLUE,positive
172416.0,"Wedbush Downgrades bluebird bio, Inc. - Common Stock to Neutral, Lowers Price Target to $131",2019-05-15 07:20:00-04:00,BLUE,negative
172417.0,"bluebird bio Q1 EPS $(2.99) Misses $(2.8) Estimate, Sales $12.47M Miss $13.24M Estimate",2019-05-02 16:53:00-04:00,BLUE,negative
172418.0,Celgene And Bluebird Bio Highlight Results From Ongoing Multicenter Phase 1 Study Of bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine,2019-05-01 18:19:00-04:00,BLUE,positive
172419.0,Shares of several healthcare companies are trading lower after Trump renewed his efforts to repeal and replace the Affordable Care Act; the Department of Justice moved to accelerate the appeal process in hopes to invalidate the ACA as unconstitutional.,2019-04-17 10:38:00-04:00,BLUE,positive
172420.0,"Jim Cramer Weighs In On Oracle, Bluebird Bio And More",2019-04-16 07:51:00-04:00,BLUE,neutral
172421.0,bluebird bio Issues Press Release Confirming Positive CHMP Opinion For ZYNTEGLO,2019-03-29 07:44:00-04:00,BLUE,positive
172422.0,EMA Panel Recommends Approval Of bluebird bio's Zynteglo For Treatment Of A Type Of Blood Disorder With Conditions,2019-03-29 07:30:00-04:00,BLUE,positive
172423.0,Adam Feuerstein Tweets: $BLUE the EMA's CHMP issued a positive opinion (approval recommendation) of lentiglobin gene therapy for transfusion-dependent beta thalassemia. Brand name: Zyntelgo.,2019-03-25 16:22:00-04:00,BLUE,positive
172424.0,"'The sickle cell gene therapy featured on 60 Minutes last night was $BLUE Lentiglobin. I wasn't sure bc Bluebird was not mentioned, had no involvement in the story...' -Tweet From STAT News' Adam Feuerstein",2019-03-11 12:28:00-04:00,BLUE,neutral
172425.0,"Benzinga's Top Upgrades, Downgrades For March 5, 2019",2019-03-05 09:12:00-05:00,BLUE,positive
172426.0,Leerink Swann Downgrades bluebird bio to Market Perform,2019-03-05 07:31:00-05:00,BLUE,neutral
172427.0,"Benzinga's Top Upgrades, Downgrades For February 26, 2019",2019-02-26 09:59:00-05:00,BLUE,positive
172428.0,Cowen & Co. Initiates Coverage On bluebird bio with Outperform Rating,2019-02-26 07:36:00-05:00,BLUE,neutral
172429.0,72 Biggest Movers From Yesterday,2019-02-26 05:31:00-05:00,BLUE,neutral
172430.0,42 Stocks Moving In Monday's Mid-Day Session,2019-02-25 12:25:00-05:00,BLUE,neutral
172431.0,Shares of gene therapy companies are trading higher after Roche announced it would acquire Spark Therapeutics for $114.50 per share in cash.,2019-02-25 09:38:00-05:00,BLUE,positive
172432.0,Bluebird Bio shares are trading higher in sympathy with Roche's acquisition of Spark Therapeutics earlier Monday.,2019-02-25 09:28:00-05:00,BLUE,positive
172433.0,"The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data",2019-02-22 08:50:00-05:00,BLUE,neutral
172434.0,"bluebird bio Q4 EPS $(2.72) Beats $(2.86) Estimate, Sales $19.24M Beat $8.12M Estimate",2019-02-21 17:11:00-05:00,BLUE,neutral
172435.0,"Bluebird Bio Announces Chip Baird CFO, Current CFO to Remain with Company in New Role",2019-02-11 06:31:00-05:00,BLUE,neutral
172436.0,Goldman Sachs Steps To The Sidelines On Crispr Therapeutics,2019-01-28 09:33:00-05:00,BLUE,neutral
172437.0,10 Biggest Price Target Changes For Wednesday,2019-01-23 09:52:00-05:00,BLUE,neutral
172438.0,"Canaccord Genuity Maintains Buy on bluebird bio, Lowers Price Target to $161",2019-01-23 07:49:00-05:00,BLUE,negative
172439.0,"Bluebird Bio shares are trading higher after the company announced a collaboration with Inhibrx to research, develop and commercialize CAR T cell immunotherapies.",2019-01-07 10:25:00-05:00,BLUE,positive
172440.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,BLUE,neutral
172441.0,"Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation",2018-12-20 11:10:00-05:00,BLUE,positive
172442.0,Raymond James Initiates Coverage On bluebird bio with Strong Buy Rating,2018-12-20 09:19:00-05:00,BLUE,positive
172443.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $125",2018-12-19 08:13:00-05:00,BLUE,negative
172444.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Fri., Dec. 7, 2018",2018-12-10 11:01:00-05:00,BLUE,negative
172445.0,10 Biggest Price Target Changes For Thursday,2018-12-06 09:43:00-05:00,BLUE,neutral
172446.0,"Benzinga's Top Upgrades, Downgrades For December 6, 2018",2018-12-06 09:15:00-05:00,BLUE,positive
172447.0,"PiperJaffray Downgrades bluebird bio to Neutral, Lowers Price Target to $120",2018-12-06 06:14:00-05:00,BLUE,negative
172448.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,BLUE,neutral
172449.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,BLUE,neutral
172450.0,bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at ASH 2018,2018-12-04 04:52:00-05:00,BLUE,neutral
172451.0,bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia with CHP at ASH 2018,2018-12-04 04:51:00-05:00,BLUE,neutral
172452.0,46 Stocks Moving In Monday's Mid-Day Session,2018-12-03 12:37:00-05:00,BLUE,neutral
172453.0,28 Stocks Moving In Monday's Pre-Market Session,2018-12-03 08:13:00-05:00,BLUE,neutral
172454.0,"bluebird bio, Celgene Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH 2018",2018-12-02 21:36:00-05:00,BLUE,neutral
172455.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,BLUE,neutral
172456.0,bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent β-Thalassemia and Sickle Cell Disease at ASH 2018,2018-12-02 10:14:00-05:00,BLUE,neutral
172457.0,Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns',2018-11-28 13:05:00-05:00,BLUE,neutral
172458.0,"Benzinga's Top Upgrades, Downgrades For November 28, 2018",2018-11-28 08:59:00-05:00,BLUE,positive
172459.0,"Leerink Swann Initiates Coverage On bluebird bio with Outperform Rating, Announces $145 Price Target",2018-11-28 08:52:00-05:00,BLUE,neutral
172460.0,"Leerink Initiates Coverage On bluebird bio With Outperform Rating, $145 Price Target, On Rocket Pharma With Outperform Rating, $22 Price Target",2018-11-27 16:37:00-05:00,BLUE,neutral
172461.0,bluebird bio Option Alert: Dec 21 $110 Puts Sweep (5) near the Bid: 1029 @ $6.09 vs 309 OI; Ref=$121.07,2018-11-27 15:04:00-05:00,BLUE,positive
172462.0,"Celgene, bluebird bio Report Enrollment Completed In Pivotal KarMMa Study Of bb2121 In Patients With Relapsed, Refractory Multiple Myeloma",2018-11-27 07:30:00-05:00,BLUE,neutral
172463.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $185",2018-11-05 12:41:00-05:00,BLUE,negative
172464.0,Janney Upgrades bluebird bio Ahead Of Sickle Cell Presentation,2018-11-05 12:09:00-05:00,BLUE,neutral
172465.0,"Wedbush Maintains Outperform on bluebird bio, Lowers Price Target to $166",2018-11-05 10:43:00-05:00,BLUE,negative
172466.0,"Janney Capital Upgrades bluebird bio to Buy, Maintains $170 Price Target",2018-11-05 06:33:00-05:00,BLUE,neutral
172467.0,"bluebird bio Q3 EPS $(2.73) Beats $(2.87) Estimate, Sales $11.528M Beat $7.51M Estimate",2018-11-01 16:00:00-04:00,BLUE,neutral
172468.0,"Stocks Which Set New 52-Week Low Yesterday, October 29th",2018-10-30 12:40:00-04:00,BLUE,negative
172469.0,"The Daily Biotech Pulse: Pfizer And Allergan Earnings, CFO Departures At Acadia And Assertio",2018-10-30 08:00:00-04:00,BLUE,neutral
172470.0,"Stocks Which Set New 52-Week Low Friday, October 26th",2018-10-29 09:56:00-04:00,BLUE,negative
172471.0,"The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price",2018-10-25 08:03:00-04:00,BLUE,negative
172472.0,"Stocks Which Set New 52-Week Low Yesterday, October 23rd",2018-10-24 10:06:00-04:00,BLUE,negative
172473.0,"Stocks Which Set New 52-Week Low Yesterday, October 22nd",2018-10-23 09:54:00-04:00,BLUE,negative
172474.0,"The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares",2018-10-23 08:35:00-04:00,BLUE,positive
172475.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Lowers Price Target to $186",2018-10-15 07:12:00-04:00,BLUE,negative
172476.0,"Stocks Which Set New 52-Week Low Yesterday, October 11th",2018-10-12 11:30:00-04:00,BLUE,negative
172477.0,"bluebird bio 8-K Shows EMA Accepted Co.'s Marketing Authorization Application For LentiGlobin As Treatment For Adolescents, Adults With Transfusion-Dependent ß-Thalassemia",2018-10-05 06:22:00-04:00,BLUE,positive
172478.0,"Jim Cramer Weighs In On Alibaba, Nucor, Total And More",2018-09-25 07:43:00-04:00,BLUE,neutral
172479.0,"bluebird bio 8-K Shows Co. COO, Susanna High, To Leave, Effective Jan. 4, 2019",2018-09-11 08:34:00-04:00,BLUE,positive
172480.0,"Wells Fargo Securities Health Care Conference Concludes Today, Presenters Include: Universal Health Services, Tenet Healthcare, Bluebird Bio",2018-09-06 06:18:00-04:00,BLUE,positive
172481.0,"The Daily Biotech Pulse: Biohaven In-Licenses Drug, Retrophin's Debt Offering, ProQR And Bluebird Report Positive Trial Results",2018-09-05 08:28:00-04:00,BLUE,positive
172482.0,Bluebird Bio Reaches Agreement With FDA And EMA On Clinical Development Program To Support Future Marketing Applications For Lenti-D In CALD,2018-09-05 06:15:00-04:00,BLUE,positive
172483.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2018-09-02 09:41:00-04:00,BLUE,neutral
172484.0,UPDATE: bluebird Says Gritstone Oncology Will Receive $20M In Upfront Payment With Added $10M In Form Of Series C Preferred Equity Investment,2018-08-23 06:33:00-04:00,BLUE,neutral
172485.0,bluebird bio Reports Strategic Collaboration With Gritstone Oncology For Development Of Novel Cancer Cell Therapies,2018-08-23 06:32:00-04:00,BLUE,negative
172486.0,"Express Scripts in Talks With Biomarin Pharmaceutical, Spark Therapeutics, Bluebird Bio to have Specialty Pharmaceutical Business Exclusively Distribute Their New Hemophilia Treatments",2018-08-15 04:20:00-04:00,BLUE,positive
172487.0,Regeneron To Make $100M bluebird bio Investment In Cancer Research Collaboration,2018-08-06 11:02:00-04:00,BLUE,negative
172488.0,Benzinga Pro's 5 Stocks To Watch Today,2018-08-06 08:51:00-04:00,BLUE,neutral
172489.0,26 Stocks Moving In Monday's Pre-Market Session,2018-08-06 08:04:00-04:00,BLUE,neutral
172490.0,"bluebird bio and Regeneron Announce Cancer Collaboration, Regeneron to Invest $100M in bluebird Stock at $238.10/Share",2018-08-06 06:35:00-04:00,BLUE,negative
172491.0,"bluebird bio Q2 EPS $(2.91) Misses $(2.35) Estimate, Sales $7.851M Miss $9.64M Estimate",2018-08-02 06:40:00-04:00,BLUE,negative
172492.0,bluebird bio's LentiGlobin Gene Therapy Granted Accelerated Assessment by European Medicines Agency,2018-07-26 16:35:00-04:00,BLUE,positive
172493.0,bluebird bio Prices 3.3M Share Public Offering of Common Stock @$162.50/Share,2018-07-24 21:09:00-04:00,BLUE,positive
172494.0,"Benzinga's Daily Biotech Pulse: Celgene's Lymphoma Trial Meets Endpoint, Merit Medical's Strong Q2, Bluebird Bio Offering",2018-07-24 08:53:00-04:00,BLUE,positive
172495.0,Bluebird Bio Announces $400M Common Stock Offering,2018-07-23 16:01:00-04:00,BLUE,neutral
172496.0,"bluebird bio 8-K Shows Celgene Amended Study Protocol For KarMMa Study Of bb2121 In Patients With Relapsed, Refractory Multiple Myeloma: Dose Range For Study Will Be 150-450 x 10^6 CAR+ T Cells, Enrollment Raised To Up To 140 Patients",2018-07-12 16:38:00-04:00,BLUE,neutral
172497.0,"Acceleron Pharma Rallies After Phase 3 MDS Data, But Goldman Sachs Still Isn't Buying",2018-06-29 11:10:00-04:00,BLUE,neutral
172498.0,bluebird bio Option Alert: Jul 20 $170 Calls at the Ask: 622 @ $5.8 vs 387 OI; Earnings 8/1 After Close [est] Ref=$162.125,2018-06-29 11:06:00-04:00,BLUE,positive
172499.0,"Evercore ISI Says Bluebird Bio Has Path To Commercialization, Madrigal Pharma Outpaced By Mid-Cap Alternatives",2018-06-23 10:21:00-04:00,BLUE,neutral
172500.0,8 Biggest Price Target Changes For Tuesday,2018-06-19 09:42:00-04:00,BLUE,neutral
172501.0,"Benzinga's Top Upgrades, Downgrades For June 19, 2018",2018-06-19 09:17:00-04:00,BLUE,positive
172502.0,"Evercore ISI Group Upgrades bluebird bio to Outperform, Raises Price Target to $230",2018-06-19 07:38:00-04:00,BLUE,neutral
172503.0,"UPDATE: bluebird bio Offers Group A, B, C, Results For LentiGlobin In Severe Sickle Cell Treatment Trial",2018-06-15 06:16:00-04:00,BLUE,negative
172504.0,UPDATE: bluebird bio Says 'First Group C patient generating a normal total hemoglobin of 14.2 g/dL with over 60% anti-sickling HbAT87Q at 6 months',2018-06-15 06:15:00-04:00,BLUE,neutral
172505.0,bluebird bio Reports New Interim Data From Phase 1 HGB-206 Study Of LentiGlobin In Patients with Severe Sickle Cell Disease; All patients (n=4) in Group C with ≥ 3 months follow-up consistently producing ≥ 30% anti-sickling HbAT87Q,2018-06-15 06:15:00-04:00,BLUE,negative
172506.0,"'New $BLUE data show promising benefits for gene therapy, if they last statnews.com/2018/06/15/blu… Your latest sickle cell and beta-thalassemia update.'",2018-06-15 06:08:00-04:00,BLUE,positive
172507.0,"UPDATE: bluebird bio Highlights Results On HGB-207, HGB-204",2018-06-15 06:06:00-04:00,BLUE,neutral
172508.0,UPDATE: bluebird bio Says Co. On Track To File Marketing Authorization Application In EU In 2H'18,2018-06-15 06:05:00-04:00,BLUE,neutral
172509.0,bluebird bio Reports Presentation Of Data From Phase 1/2 HGB-204 Study In Adolescents With Transfusion-Dependent β-Thalassemia at Annual Congress of the European Hematology Association,2018-06-15 06:05:00-04:00,BLUE,neutral
172510.0,"The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs",2018-06-10 17:29:00-04:00,BLUE,neutral
172511.0,"Jefferies 2018 Global Healthcare Conference Continues Today, Presenters Include: bluebird bio, GlycoMimetics, Five Prime Therapeutics, GTx, ImmunoGen, Puma Biotech, and Deciphera Pharma",2018-06-07 07:13:00-04:00,BLUE,neutral
172512.0,Bluebird Bio's Multiple Myeloma Data Reinforces Canaccord Genuity's Bullish Thesis,2018-06-04 17:09:00-04:00,BLUE,neutral
172513.0,28 Stocks Moving In Monday's Pre-Market Session,2018-06-04 08:11:00-04:00,BLUE,neutral
172514.0,Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO,2018-06-01 08:16:00-04:00,BLUE,neutral
172515.0,"PiperJaffray Assumes bluebird bio at Overweight, Announces Price Target $240",2018-05-31 08:11:00-04:00,BLUE,negative
172516.0,The Week Ahead In Biotech: ASCO Presentations In The Spotlight,2018-05-26 11:07:00-04:00,BLUE,neutral
172517.0,bluebird bio Reports FDA Granted Breakthrough Therapy Designation To Lenti-D For Treatment Of Cerebral Adrenoleukodystrophy,2018-05-23 08:04:00-04:00,BLUE,positive
172518.0,UPDATE: FDA Is Planning Easier Approval For Experimental Gene Therapies,2018-05-22 12:47:00-04:00,BLUE,positive
172519.0,Watching Gene Therapy Stocks Amid Report FDA Could Allow Gene Therapy Approval On Surrogate Endpoints,2018-05-22 12:46:00-04:00,BLUE,positive
172520.0,"Adam Feuerstein Tweet: $BLUE — I saw some confusion last night re: #ASCO18 abstract for bb2121. To clarify, no new data in the ASCO abstract, including patient deaths. Already known. The update will be presented at the meeting.",2018-05-17 06:14:00-04:00,BLUE,negative
172521.0,"BMO Capital Maintains Outperform on bluebird bio, Lowers Price Target to $216.00",2018-05-03 08:13:00-04:00,BLUE,negative
172522.0,"bluebird bio Q1 EPS $(2.31) Misses $(2.07) Estimate, Sales $15.957M Beat $5.59M Estimate",2018-05-02 16:28:00-04:00,BLUE,negative
172523.0,31 Stocks Moving In Monday's Mid-Day Session,2018-04-09 12:32:00-04:00,BLUE,neutral
172524.0,20 Stocks Moving In Monday's Pre-Market Session,2018-04-09 08:06:00-04:00,BLUE,neutral
172525.0,"UPDATE: bluebird, Celgene To Share 50% Of US Costs, Profits, bluebird Will Receive Milestone, Royalty Payments In Ex-US Sales",2018-03-28 08:01:00-04:00,BLUE,positive
172526.0,"bluebird bio, Celgene Reports Deal To Co-Develop, Promote Anti-BCMA CAR T Cell Therapy bb2121 In US",2018-03-28 08:01:00-04:00,BLUE,positive
172527.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to $209.00",2018-03-21 09:29:00-04:00,BLUE,neutral
172528.0,"bluebird bio Shares Continue Lower Following Word Of Negative Comments From Favus On Fri., Response From STAT News' Adam Feuerstein: Stock Down 5.9% Tues., Down 14% From Thurs. Close; Not Seeing New News To Justify Move Lower Tues.",2018-03-20 11:55:00-04:00,BLUE,negative
172529.0,"Adam Feuerstein Tweets: Well… honestly, Favus is just making a trading call. Look at $BLUE chart. Not hard to do with an important catalyst coming.",2018-03-16 14:13:00-04:00,BLUE,positive
172530.0,Adam Feuerstein Tweets (2/2): High expectations for BCMA program. Could see more patient relapses. $CELG JUNO deal a negative.,2018-03-16 10:16:00-04:00,BLUE,negative
172531.0,Adam Feuerstein Tweets (1/2): I read the Favus note on $BLUE. He basically sets up the stock as a short trade going into ASCO: Stock price flying.,2018-03-16 10:16:00-04:00,BLUE,neutral
172532.0,"Barclays Global Healthcare Conference Concludes Today, Presenters Include: Tenet Healthcare, bluebird bio, and Revance Therapeutics",2018-03-15 09:14:00-04:00,BLUE,neutral
172533.0,"Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued",2018-03-14 09:53:00-04:00,BLUE,positive
172534.0,"Benzinga's Top Upgrades, Downgrades For March 14, 2018",2018-03-14 09:35:00-04:00,BLUE,positive
172535.0,"Janney Capital Initiates Coverage On bluebird bio with Neutral Rating, Announces $220.00 Price Target",2018-03-14 06:32:00-04:00,BLUE,neutral
172536.0,William Blair: Bluebird Bio Could See Another 'Blue Ribbon Year' In 2018,2018-03-05 14:44:00-05:00,BLUE,neutral
172537.0,"William Blair Initiates Coverage On bluebird bio with Outperform Rating, Announces $242.00 Price Target",2018-03-05 09:08:00-05:00,BLUE,neutral
172538.0,"Morgan Stanley Maintains Equal-Weight on bluebird bio, Raises Price Target to $152.00",2018-02-26 07:30:00-05:00,BLUE,neutral
172539.0,5 Biggest Price Target Changes For Thursday,2018-02-22 10:12:00-05:00,BLUE,neutral
172540.0,"Bank of America Maintains Neutral on bluebird bio, Raises Price Target to $218.00",2018-02-22 08:52:00-05:00,BLUE,neutral
172541.0,"BMO Capital Maintains Outperform on bluebird bio, Raises Price Target to $222.00",2018-02-22 08:04:00-05:00,BLUE,neutral
172542.0,"bluebird bio Reports Q4 Net Loss $117.2M, EPS $(2.52), Sales $4.168M vs $7.1M Est.",2018-02-21 16:30:00-05:00,BLUE,negative
172543.0,"13F From Perceptive Advisors Late Wednesday Shows Increased Stake In Abiomed, Neurocrine Biosciences, VBI Vaccines; New Stake In Agile Therapeutics, Amgen, bluebird bio, Arena Pharma, Revance Therapeutics; Exited Stake In Achaogen, OraSure Technologies",2018-02-15 10:41:00-05:00,BLUE,positive
172544.0,"Leerink Partners Global Healthcare Conference Begins Today, Presenters Include: Dova Pharma, Heron Therapeutics, Sage Therapeutics, Enanta, The Medicines Company, Puma Biotech, Dicerna Pharma, Biogen, bluebird bio, and Alexion Pharma",2018-02-14 07:06:00-05:00,BLUE,neutral
172545.0,34 Stocks Moving In Thursday's Mid-Day Session,2018-01-25 13:29:00-05:00,BLUE,neutral
172546.0,Leerink: Bluebird Bio's Catalysts Are Priced In,2018-01-25 10:24:00-05:00,BLUE,neutral
172547.0,"Benzinga's Top Upgrades, Downgrades For January 25, 2018",2018-01-25 09:37:00-05:00,BLUE,positive
172548.0,Celgene CEO Says Working With bluebird bio To Develop BB2121 Car-T Therapy For Myeloma Is A Top Priority And That Its Positioned To Launch 2 Car-T Therapies In Blood Cancers In Next 3 Years,2018-01-25 09:26:00-05:00,BLUE,positive
172549.0,26 Stocks Moving In Thursday's Pre-Market Session,2018-01-25 08:06:00-05:00,BLUE,neutral
172550.0,Leerink Swann Downgrades bluebird bio to Market Perform,2018-01-25 07:23:00-05:00,BLUE,neutral
172551.0,"Cara Therapeutics Shares Up 19.24% As Co. Mentioned In Earlier Opinion Piece As Potential M&A Target; Other Mentions Include: BMRN -0.66%, BLUE +3.87%, ACAD -0.3%, INCY +0.4%",2018-01-24 13:40:00-05:00,BLUE,positive
172552.0,Pharma M&A Picks Up Momentum,2018-01-23 13:56:00-05:00,BLUE,neutral
172553.0,Bluebird Bio Up On Buyout Speculation After Celgene-Juno Deal,2018-01-23 11:13:00-05:00,BLUE,neutral
172554.0,38 Biggest Movers From Yesterday,2018-01-23 04:55:00-05:00,BLUE,neutral
172555.0,32 Stocks Moving In Monday's Mid-Day Session,2018-01-22 12:46:00-05:00,BLUE,neutral
172556.0,30 Stocks Moving In Monday's Pre-Market Session,2018-01-22 07:58:00-05:00,BLUE,neutral
172557.0,A Survey Of Celgene's M&A Strategy,2018-01-19 09:41:00-05:00,BLUE,neutral
172558.0,44 Biggest Movers From Yesterday,2018-01-18 04:43:00-05:00,BLUE,neutral
172559.0,Wall Street Reacts To Celgene's Reported Interest In Juno,2018-01-17 15:39:00-05:00,BLUE,positive
172560.0,38 Stocks Moving In Wednesday's Mid-Day Session,2018-01-17 12:28:00-05:00,BLUE,neutral
172561.0,bluebird bio Shares Trading Up 10% Following Report Celgene In Talks To Buy Juno; bluebird Likely Being Viewed As A Sympathy Play,2018-01-17 10:15:00-05:00,BLUE,positive
172562.0,"From JP Morgan Healthcare Conference: bluebird bio Expecting Filing for US, EU Approval Of B2121 For Multiple Myeloma In '19",2018-01-09 10:52:00-05:00,BLUE,positive
172563.0,bluebird CEO Sees 3 Regulatory Filings By End Of 2019,2018-01-09 10:38:00-05:00,BLUE,neutral
172564.0,"JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics",2018-01-09 09:02:00-05:00,BLUE,positive
172565.0,Adam Feuerstein Tweets: $BLUE EMA filing for beta-thal gene therapy will be towards end of year. A bit later than some had hoped for.,2018-01-08 08:15:00-05:00,BLUE,positive
172566.0,"Goldman Sachs Healthcare CEOs Unscripted Conference Taking Place Today; Presenters Include Agilent, Bluebird Bio, Boston Scientific, Alexion, Eli Lilly, and Alnylam",2018-01-04 06:54:00-05:00,BLUE,neutral
172567.0,The Companies That Led 2017's Biotech Rally,2017-12-22 09:50:00-05:00,BLUE,neutral
172568.0,Oppenheimer Initiates Coverage On bluebird bio with Perform Rating,2017-12-21 09:00:00-05:00,BLUE,neutral
172569.0,3 Biotech Pipeline Areas To Keep An Eye On In 2018,2017-12-20 12:37:00-05:00,BLUE,neutral
172570.0,"ICYMI: T-Mobile Terrorizes Telecom Space, 2017 ASH Recap, Bitcoin Continues To Dominate The News Cycle",2017-12-14 07:18:00-05:00,BLUE,negative
172571.0,30 Biggest Movers From Yesterday,2017-12-14 05:25:00-05:00,BLUE,neutral
172572.0,32 Stocks Moving In Wednesday's Mid-Day Session,2017-12-13 12:37:00-05:00,BLUE,neutral
172573.0,"ASH 2017 Highlights: Gilead, Novartis, Juno, Bluebird Bio And More",2017-12-13 12:31:00-05:00,BLUE,neutral
172574.0,Analyst Doubts Bluebird Bio Shares — Up 200% In 2017 — Can Fly Much Higher,2017-12-13 10:24:00-05:00,BLUE,neutral
172575.0,"Benzinga's Top Upgrades, Downgrades For December 13, 2017",2017-12-13 09:01:00-05:00,BLUE,positive
172576.0,Maxim Group Downgrades bluebird bio to Hold,2017-12-13 07:49:00-05:00,BLUE,neutral
172577.0,A Peek Into The Markets: U.S. Stock Futures Edge Higher; Fed Decision In Focus,2017-12-13 06:52:00-05:00,BLUE,neutral
172578.0,bluebird bio Prices ~3.2M Share Offering @$185/Share,2017-12-13 04:01:00-05:00,BLUE,positive
172579.0,"ICYMI: Blockchain, Bitcoin, And Biotech",2017-12-12 07:18:00-05:00,BLUE,neutral
172580.0,42 Biggest Movers From Yesterday,2017-12-12 05:56:00-05:00,BLUE,neutral
172581.0,"7 Stocks To Watch For December 12, 2017",2017-12-12 04:47:00-05:00,BLUE,neutral
172582.0,7 Stocks Moving In Monday's After-Hours Session,2017-12-11 17:13:00-05:00,BLUE,neutral
172583.0,11 Biotech Stocks Moving From ASH 2017,2017-12-11 16:24:00-05:00,BLUE,neutral
172584.0,bluebird bio Reports Offering Of $600M In Common Shares,2017-12-11 16:01:00-05:00,BLUE,positive
172585.0,Mid-Afternoon Market Update: NASDAQ Up 0.5%; bluebird bio Shares Spike Higher,2017-12-11 14:31:00-05:00,BLUE,positive
172586.0,3 Stocks In Focus As Biotech M&A Hopes For 2018 Rise,2017-12-11 12:52:00-05:00,BLUE,positive
172587.0,Goldman: Bluebird Bio Is One Step Closer To A Sickle Cell Cure,2017-12-11 12:42:00-05:00,BLUE,neutral
172588.0,30 Stocks Moving In Monday's Mid-Day Session,2017-12-11 12:07:00-05:00,BLUE,neutral
172589.0,Jefferies Calls Bluebird Bio The 'Star' Of This Year's ASH Meeting,2017-12-11 10:53:00-05:00,BLUE,neutral
172590.0,Mid-Morning Market Update: Markets Edge Higher; 3M To Sell Communication Markets Division For $900M,2017-12-11 10:26:00-05:00,BLUE,neutral
172591.0,5 Biggest Price Target Changes For Monday,2017-12-11 09:48:00-05:00,BLUE,neutral
172592.0,"Benzinga's Top Upgrades, Downgrades For December 11, 2017",2017-12-11 09:31:00-05:00,BLUE,positive
172593.0,"After Data Release, Cantor Fitzgerald Doubles Bluebird Bio Price Target",2017-12-11 09:19:00-05:00,BLUE,neutral
172594.0,"bluebird bio Reports Updated Data From HGB-205 Study Of LentiGlobin Gene Therapy In Patients With Severe Sickle Cell Disease, Transfusion-Dependent ß-Thalassemia",2017-12-11 09:09:00-05:00,BLUE,negative
172595.0,"Suntrust Raises Price Target On bluebird bio From $163 To $223 Based On 'Robust' Durability Data Presented On All Programs At ASH Conference, Increases Probability Of Success In SCD Program From 40% to 60% And Car-T Program from 35% to 55%",2017-12-11 08:50:00-05:00,BLUE,positive
172596.0,Jefferies Upgrades bluebird bio to Buy,2017-12-11 08:35:00-05:00,BLUE,neutral
172597.0,22 Stocks Moving In Monday's Pre-Market Session,2017-12-11 08:15:00-05:00,BLUE,neutral
172598.0,"Adam Feuerstein Tweets: $BLUE had a good #ASH17. 

BCMA CAR-T - statnews.com/2017/12/10/car…

beta-thal and sickle cell gene therapy - statnews.com/2017/12/11/blu…",2017-12-11 07:25:00-05:00,BLUE,positive
172599.0,Bluebird Bio Announces Updated Clinical Results from Ongoing Phase 1 Multicenter Study of LentiGlobin Gene Therapy in Severe Sickle Cell Disease at #ASH2017,2017-12-10 17:41:00-05:00,BLUE,negative
172600.0,Bluebird Bio Presents New Dabluebird bio Presents New Data from Clinical Studies of LentiGlobin Gene Therapy in Tta from Clinical Studies of LentiGlobin™ Gene Therapy in Transfusion-Dependent β-Thalassemia at #ASH2017,2017-12-10 17:39:00-05:00,BLUE,neutral
172601.0,"Blubirdbio and TC BioPharm to Collaborate  to Research and Develop Gamma Delta CAR T Cell Product Candidates for Cancer Immunotherapy, Bluebird to Make a $16M Upfront Payment",2017-12-07 08:08:00-05:00,BLUE,negative
172602.0,"Benzinga's Top Upgrades, Downgrades For December 5, 2017",2017-12-05 09:32:00-05:00,BLUE,positive
172603.0,"Canaccord Genuity Initiates Coverage On bluebird bio with Buy Rating, Announces $202.00 Price Target",2017-12-05 07:38:00-05:00,BLUE,neutral
172604.0,"Bluebird Bio Shares Up 3.56%; Earlier Maxim Group Maintained A Buy Rating On The Co., Raising Price Target From $170 to $200, Citing Reduced Risk and Saying Valuation Hasn't Peaked",2017-11-30 12:11:00-05:00,BLUE,neutral
172605.0,"Bluebird Bio Acquires a manufacturing Facility in North Carolina, Terms Not Disclosed",2017-11-29 08:08:00-05:00,BLUE,neutral
172606.0,"Celgene Corporation, bluebird bio Report bb2121 Anti-BCMA CAR-T Cell Therapy Has Been Granted Breakthrough Therapy Designation from FDA and Prime Eligibility from EMA for Relapsed and Refractory Multiple Myeloma",2017-11-16 08:32:00-05:00,BLUE,positive
172607.0,"bluebird bio Reports First Patient Treated In HGB-212, Phase 3 Study of LentiGlobin™ in Patients with TDT, β⁰/β⁰ Genotype",2017-11-16 08:04:00-05:00,BLUE,neutral
172608.0,"13F Filing From Baker Bros Shows Increased Stake In Array BioPharma, Ascendis Pharma, BioCryst Pharmaceuticals, Slightly Reduced Stake In Bluebird Bio",2017-11-14 15:56:00-05:00,BLUE,positive
172609.0,"Shares Of bluebird bio Moving Higher In Late Afternoon Trading, Now Positive For The Day, Up 2% At $157.64 On No Apparent News",2017-11-14 15:14:00-05:00,BLUE,positive
172610.0,Omega Advisors Dissolve Stake In bluebird bio,2017-11-14 10:35:00-05:00,BLUE,neutral
172611.0,Barclays: Editas Medicine On Track To File New Drug App Next Year,2017-11-08 16:24:00-05:00,BLUE,neutral
172612.0,9 Notable Biotechs Presenting At This Year's ASH Meeting,2017-11-06 16:31:00-05:00,BLUE,neutral
172613.0,Evercore ISI Group Downgrades bluebird bio to In-Line,2017-11-06 08:53:00-05:00,BLUE,neutral
172614.0,"SunTrust Raises bluebird Price Target From $108 To $163, Firm Says BCMA Creates Significant Value And That ASH 2017 Is Next Major Catalyst For Co.",2017-11-03 13:47:00-04:00,BLUE,positive
172615.0,"Benzinga's Top Upgrades, Downgrades For November 3, 2017",2017-11-03 09:10:00-04:00,BLUE,positive
172616.0,Morgan Stanley Upgrades bluebird bio to Equal-Weight,2017-11-03 08:10:00-04:00,BLUE,neutral
172617.0,"Benzinga's Top Upgrades, Downgrades For November 2, 2017",2017-11-02 09:13:00-04:00,BLUE,positive
172618.0,BTIG Research Upgrades bluebird bio to Buy,2017-11-02 08:21:00-04:00,BLUE,neutral
172619.0,Bluebird Bio Price Target Bumped To $58 On Directional Improvements,2017-11-01 14:54:00-04:00,BLUE,positive
172620.0,Bluebird Bio Sharply Higher After Mixed Q3 Report,2017-11-01 11:41:00-04:00,BLUE,neutral
172621.0,"bluebird bio Reports Q3 EPS $(1.73) vs $(1.71) Est., Sales $7.711M vs $7.07M Est.",2017-11-01 07:39:00-04:00,BLUE,neutral
172622.0,35 Biggest Movers From Yesterday,2017-10-17 04:52:00-04:00,BLUE,neutral
172623.0,4 Biotechs Boosted By Spark Therapeutic's FDA News,2017-10-16 14:10:00-04:00,BLUE,positive
172624.0,The BLUE And The BOLD; Analyst Suggests Pair Trade Ahead Of Year-End Catalysts,2017-10-16 13:30:00-04:00,BLUE,positive
172625.0,30 Stocks Moving In Monday's Mid-Day Session,2017-10-16 12:32:00-04:00,BLUE,neutral
172626.0,"Benzinga's Top Upgrades, Downgrades For October 16, 2017",2017-10-16 09:13:00-04:00,BLUE,positive
172627.0,Evercore ISI Group Upgrades bluebird bio to Outperform,2017-10-16 07:56:00-04:00,BLUE,neutral
172628.0,"Benzinga's Top Upgrades, Downgrades For October 11, 2017",2017-10-11 09:13:00-04:00,BLUE,positive
172629.0,Jefferies Downgrades bluebird bio to Hold,2017-10-11 06:12:00-04:00,BLUE,neutral
172630.0,"UPDATE: bluebird bio's Publication In NEJM Show 'No engraftment failure, GVHD or life-threatening infections occurred; no evidence of insertional oncogenesis'",2017-10-04 15:01:00-04:00,BLUE,negative
172631.0,bluebird bio Reports Publication Of Interim Data From Starbeam Study Of Lenti-DTM Drug Product For Patients With CALD: '15/17 (88%) of the patients infused with Lenti-D drug product remain alive and free of major functional disabilities',2017-10-04 15:00:00-04:00,BLUE,positive
172632.0,12 Biggest Mid-Day Losers For Monday,2017-10-02 12:07:00-04:00,BLUE,negative
172633.0,"Bluebird Bio's Wings Clipped, Morgan Stanley Downgrades",2017-10-02 10:17:00-04:00,BLUE,neutral
172634.0,30 Stocks Moving In Monday's Pre-Market Session,2017-10-02 08:11:00-04:00,BLUE,neutral
172635.0,Morgan Stanley Downgrades bluebird bio to Underweight,2017-10-02 05:55:00-04:00,BLUE,neutral
172636.0,bluebird bio Announces 1st Patient Treated In Phase 1 Study of BB21217,2017-09-28 16:12:00-04:00,BLUE,neutral
172637.0,"Morgan Stanley Healthcare Conference Concludes Today, Presenters Include Ironwood Pharmaceuticals, Sage Therapeutics, Pfizer, TherapeuticsMD, Alnylam, bluebird bio, and Cigna",2017-09-13 09:24:00-04:00,BLUE,neutral
172638.0,bluebird bio Reports First Patient Treated In Expansion Cohort Of CRB-401 Phase 1 Study,2017-09-13 08:06:00-04:00,BLUE,neutral
172639.0,"Benzinga's Bulls And Bears For The Past Week: Disney, GE, Tesla And More",2017-09-09 16:50:00-04:00,BLUE,neutral
172640.0,Breaking Down Barclays' New Bullish Calls On Biotech,2017-09-07 15:32:00-04:00,BLUE,neutral
172641.0,"Wells Fargo Healthcare Conference Concludes Today, Presenters Include: Foundation Medicine, Tenet Healthcare, bluebird bio, Envision Healthcare, Ironwood Pharmaceuticals, Quorum Health, and Concert Pharmaceuticals",2017-09-07 08:58:00-04:00,BLUE,positive
172642.0,"Barclays Initiates Coverage On bluebird bio with Overweight Rating, Announces $151.00 Price Target",2017-09-07 07:24:00-04:00,BLUE,negative
172643.0,Why It's Useful To Know A Company's Competitors When Trading,2017-09-05 11:26:00-04:00,BLUE,positive
172644.0,18 Biggest Mid-Day Gainers For Monday,2017-08-28 12:35:00-04:00,BLUE,neutral
172645.0,25 Stocks Moving In Monday's Pre-Market Session,2017-08-28 08:16:00-04:00,BLUE,neutral
172646.0,From A(erie) To Z(ynerba): Biotech Catalysts Lined Up For Second Half Of 2017,2017-08-25 09:07:00-04:00,BLUE,neutral
172647.0,"Benzinga's Top Upgrades, Downgrades For August 17, 2017",2017-08-17 09:34:00-04:00,BLUE,positive
172648.0,"Evercore ISI Group Initiates Coverage On bluebird bio with In-Line Rating, Announces $102.00 Price Target",2017-08-17 06:48:00-04:00,BLUE,neutral
172649.0,"Wedbush PacGrow Healthcare Conference Begins Today, Presenters Include: Omeros, Bovie Medical, Bluebird Bio, Juno Therapeutics, DexCom, Tandem Diabetes, and Insulet",2017-08-15 08:40:00-04:00,BLUE,neutral
172650.0,"13F From Omega Shows Small, New Stakes In Bluebird Bio and Clovis Oncology",2017-08-14 10:30:00-04:00,BLUE,neutral
172651.0,"bluebird Reports Q2 Loss/Share $(1.73) vs. $(1.66) Est., Sales $16.7M May Not Compare To $5.21M Est.",2017-08-02 16:15:00-04:00,BLUE,neutral
172652.0,"Benzinga's Top Upgrades, Downgrades For July 27, 2017",2017-07-27 08:57:00-04:00,BLUE,positive
172653.0,"Bernstein Initiates Coverage On bluebird bio with Market Perform Rating, Announces $109.00 Price Target",2017-07-27 07:56:00-04:00,BLUE,neutral
172654.0,"Benzinga's Top Upgrades, Downgrades For June 30, 2017",2017-06-30 09:20:00-04:00,BLUE,positive
172655.0,"After Bluebird's 75% Gain In 2017, Analysts At BTIG Downgrade To Neutral",2017-06-30 08:50:00-04:00,BLUE,positive
172656.0,BTIG Research Downgrades bluebird bio to Neutral,2017-06-30 07:41:00-04:00,BLUE,neutral
172658.0,Here's The Beef With Bluebird's Starbeam Study Results,2017-06-27 10:48:00-04:00,BLUE,neutral
172659.0,UPDATE: bluebird bio Says Expansion Cohort Enrolling Added Patients To Gain European Manufacturing Experience,2017-06-26 16:08:00-04:00,BLUE,positive
172660.0,bluebird bio Reports $350M Common Stock Offering,2017-06-26 16:07:00-04:00,BLUE,neutral
172661.0,UPDATE: bluebird bio Says 88% Of Patients In Initial Study Cohort Remain Free Of MFDs At 24 Months,2017-06-26 16:05:00-04:00,BLUE,positive
172662.0,8-K from bluebird bio Shows Topline Interim Data From Starbeam Study Of Lenti-D Product In CALD,2017-06-26 16:04:00-04:00,BLUE,neutral
172663.0,12 Biggest Mid-Day Losers For Friday,2017-06-23 13:06:00-04:00,BLUE,negative
172664.0,20 Stocks Moving In Friday's Pre-Market Session,2017-06-23 08:19:00-04:00,BLUE,neutral
172665.0,UPDATE: bluebird bio Says HGB-205 In Severe Sickle Cell Showed Clinically Meaningful Improvement In Symptoms,2017-06-23 07:03:00-04:00,BLUE,positive
172666.0,"bluebird bio Offers New Data From HGB-205 Study Of LentiGlobin Drug Product In Patients With TDT, SCD: 3 Patients Have Discontinued Iron Chelation",2017-06-23 07:03:00-04:00,BLUE,neutral
172667.0,"bluebird bio Reports Early Data From Phase 3 HGB-207 Study Of LentiGlobin Drug Product: DP VCN, LVV+ In HGB-207 Consistently Higher Than In HGB-204 With Median DP VCN Of 3.0",2017-06-23 07:01:00-04:00,BLUE,neutral
172668.0,"Adam Feuerstein Highlights STAT News Article In Tweet 'Timely w/ $GBT $BLUE updates imminent --> W/ rapper's death, harsh spotlight on slow progress against sickle cell'",2017-06-21 14:30:00-04:00,BLUE,negative
172670.0,bluebird bio Shares Down 1.5% Following Mid-Day Downgrade From Standpoint Research From Buy To Reduce,2017-06-16 14:22:00-04:00,BLUE,positive
172671.0,Standpoint Research Downgrades bluebird bio to Reduce,2017-06-16 14:22:00-04:00,BLUE,neutral
172672.0,"Jefferies Health Care Conference Concludes Today, Presenters Include: Mazor Robotic, bluebird bio, and Ocular Therapeutix",2017-06-09 07:51:00-04:00,BLUE,positive
172673.0,The Only Bullish Scenario For Juno Therapeutics: Its CEO May Get Fired,2017-06-08 10:05:00-04:00,BLUE,negative
172674.0,"Companies Holding Shareholder Meetings Today Include: Aerie Pharma, Agile Therapeutics, bluebird bio, Bojangles, Comcast, Clovis Oncology, Etsy, Egalet, Dave And Busters, Ingersoll-Rand, Priceline, Lululemon, Rent-A-Center, Splunk, & Zoe's Kitchen",2017-06-08 09:41:00-04:00,BLUE,neutral
172675.0,15 Biggest Mid-Day Gainers For Wednesday,2017-06-07 12:45:00-04:00,BLUE,neutral
172676.0,22 Stocks Moving In Wednesday's Pre-Market Session,2017-06-07 08:05:00-04:00,BLUE,neutral
172677.0,18 Biggest Mid-Day Gainers For Tuesday,2017-06-06 12:30:00-04:00,BLUE,neutral
172678.0,bluebird Shares Showing Weakness As Traders Pass Around Vague Reports Of Potential Undisclosed Lawsuit,2017-06-06 12:23:00-04:00,BLUE,negative
172679.0,Attention Bluebird Bio Investors: Analyst Sees Upside Following Strong Therapy Results,2017-06-06 11:54:00-04:00,BLUE,positive
172680.0,5 Biggest Price Target Changes For Tuesday,2017-06-06 09:55:00-04:00,BLUE,neutral
172681.0,"Benzinga's Top Upgrades, Downgrades For June 6, 2017",2017-06-06 09:27:00-04:00,BLUE,positive
172682.0,The Market In 5 Minutes,2017-06-06 09:00:00-04:00,BLUE,neutral
172683.0,"BMO Capital Upgrades bluebird bio to Outperform, Raises Price Target to $108.00",2017-06-06 06:26:00-04:00,BLUE,neutral
172684.0,12 Biggest Mid-Day Gainers For Monday,2017-06-05 12:35:00-04:00,BLUE,neutral
172685.0,Bluebird Bio and Cengine Gives Update on Study of bb2121 Anti-BCMA CAR T Cell Therapy,2017-06-05 07:32:00-04:00,BLUE,neutral
172686.0,"Standpoint Research Initiates Coverage On bluebird bio with Buy Rating, Announces $110.00 Price Target",2017-05-30 09:52:00-04:00,BLUE,neutral
172687.0,"bluebird bio Reports Q1 EPS $(1.68) vs $(1.78) Est., Sales $6.832M vs $2.12M Est.",2017-05-03 16:06:00-04:00,BLUE,neutral
172688.0,bluebird bio Reports Entered Into Lentiviral Vector Patent License Deal with Glaxo for Commercialization of Gene Therapies,2017-05-02 08:17:00-04:00,BLUE,neutral
172689.0,Bluebird Bio to License IP to Novartis,2017-05-02 08:05:00-04:00,BLUE,neutral
172690.0,Adam Feuerstein Tweets: $BLUE (short) vs $BLCM (long) report circulating today filled w/ errors and misleading statements. First posted on Seeking Alpha April 10.,2017-04-18 10:24:00-04:00,BLUE,negative
172691.0,"Pluvia Securities Out With Long/Short Trade Idea, Bellicum Long and Bluebird Bio Short As Firm Says Bellicum Pipeline Beats/Obsoletes BLUE's 3 Lead Drug Candidates",2017-04-18 10:14:00-04:00,BLUE,positive
172692.0,"Barclays Global Healthcare Conference Begins Today; Presenters Include Johnson & Johnson, Alnylam, Axovant, Paraxel, Gilead, bluebird bio, Envision Healthcare, & Tenet Healthcare",2017-03-14 08:20:00-04:00,BLUE,neutral
172693.0,bluebird bio Shares Spiking Higher,2017-03-08 10:48:00-05:00,BLUE,positive
172694.0,"Cowen Annual Healthcare Conference Continues Today; Presenters Include Regulus, Eli Lilly, Oculus, DexCom, Illumina, Allergan, Kite Pharma, Pfizer, and bluebird bio",2017-03-07 08:59:00-05:00,BLUE,neutral
172695.0,bluebird bio Reports Publication of Case Study on First Patient with Severe Sickle Cell Disease Treated with Gene Therapy in The New England Journal of Medicine,2017-03-01 17:00:00-05:00,BLUE,negative
172696.0,Maxim Group Downgrades bluebird bio To Hold,2017-02-28 09:17:00-05:00,BLUE,neutral
172697.0,Hearing bluebird bio Downgraded From Buy To Hold At Maxim,2017-02-27 13:17:00-05:00,BLUE,neutral
172698.0,Bluebird Bio Shares Could See Value Fly To $95 As 2017 Will Be A 'Catalyst-Filled Year',2017-02-23 07:43:00-05:00,BLUE,positive
172699.0,"Filing from bluebird bio Shows Registration for Mixed Securities Shelf Offering, No Terms Disclosed",2017-02-22 17:20:00-05:00,BLUE,neutral
172700.0,"bluebird bio Reports Q4 EPS $(1.88) vs $1.86) Est., Sales $1.552M vs $1.76M Est.",2017-02-22 16:30:00-05:00,BLUE,neutral
172701.0,13F from Cooperman's Omega Shows New 50K Shares Stake in bluebird bio,2017-02-14 10:49:00-05:00,BLUE,positive
172702.0,15 Biggest Mid-Day Losers For Monday,2017-02-06 12:39:00-05:00,BLUE,negative
172703.0,BlueBird Bio Wounded After Roth Downgrade,2017-02-06 10:53:00-05:00,BLUE,neutral
172704.0,The Market In 5 Minutes: One For The Thumb,2017-02-06 09:03:00-05:00,BLUE,neutral
172705.0,20 Stocks Moving In Monday's Pre-Market Session,2017-02-06 08:16:00-05:00,BLUE,neutral
172706.0,Roth Capital Downgrades bluebird bio To Neutral,2017-02-06 07:21:00-05:00,BLUE,neutral
172707.0,Piper's Chief Technical Analyst: This Market Is Entering A New Era,2017-02-03 10:40:00-05:00,BLUE,neutral
172708.0,"UPDATE: bluebird bio Says 'LentiGlobinTM drug product had a vector copy number (DP VCN) of 3.3 copies/diploid genome, with 83% of cells lentiviral vector sequence positive'",2017-02-03 08:02:00-05:00,BLUE,positive
172709.0,bluebird bio Reports First Patient Treated with LentiGlobin Drug Product Under Amended Study Protocol in HGB-206 Phase 1 Study in Patients with Sever Sickle Cell Disease,2017-02-03 08:02:00-05:00,BLUE,neutral
172710.0,"Piper's Johnson Highlights Belief Some Healthcare Names May Have Hit Near-Term Bottom, Says Likes Celgene, bluebird bio",2017-02-02 08:44:00-05:00,BLUE,positive
172711.0,Vetr Crowd Upgrades Bluebird After Trump Presser,2017-01-11 17:13:00-05:00,BLUE,neutral
172712.0,TheStreet's Adam Feuerstein Tweets '$CELG spending a lot of time talking up pipeline from partners. $BLUE $XLRN etc. #JPM17',2017-01-09 10:54:00-05:00,BLUE,neutral
172713.0,The Year's Biggest Healthcare Conference Commences This Week; Here's What You Need To Know,2017-01-09 06:33:00-05:00,BLUE,neutral
172714.0,bluebird bio and apceth Biopharma Establish Commercial Drug Product Manufacturing Agreement,2016-12-15 08:02:00-05:00,BLUE,positive
172715.0,bluebird bio Announces First Patient Treated with LentiGlobinTM Drug Product in Northstar-2 Phase 3 Trial of Patients with Transfusion-Dependent β-Thalassemia,2016-12-14 08:03:00-05:00,BLUE,neutral
172716.0,The Market In 5 Minutes: Oil Chugs Higher Amid Tillerson News,2016-12-13 09:04:00-05:00,BLUE,neutral
172717.0,"Blue Bird Q4 EPS $0.49 vs $0.42 Est, Revenue $286.4M vs $291.3M Est",2016-12-13 07:02:00-05:00,BLUE,neutral
172718.0,Biotech Winners And Losers From ASH Conference,2016-12-09 11:59:00-05:00,BLUE,negative
172719.0,18 Biggest Mid-Day Losers For Wednesday,2016-12-07 13:03:00-05:00,BLUE,negative
172720.0,20 Stocks Moving In Wednesday's Pre-Market Session,2016-12-07 08:28:00-05:00,BLUE,neutral
172721.0,bluebird bio Prices ~3.289M Share Offering @$76/Share,2016-12-07 04:19:00-05:00,BLUE,positive
172722.0,bluebird bio Announces Proposed Public Offering of $200M Common Stock,2016-12-06 16:19:00-05:00,BLUE,neutral
172723.0,8 Of The Biggest Biotech Announcements Out Of The 2016 ASH Meeting,2016-12-06 16:09:00-05:00,BLUE,neutral
172724.0,bluebird bio Provides Updates on HSC Gene Therapy Programs,2016-12-05 19:37:00-05:00,BLUE,neutral
172725.0,"American Society Of Hematology (ASH) Meeting Presenters Tonight Include Karyopharm, bluebird bio, Alnylam, Juno Therapeutics, Stemline Therapeutics, Kite Pharma, Beigene, & Prothena",2016-12-05 15:09:00-05:00,BLUE,neutral
172726.0,What Is The ASH Conference And Why Should Biotech Investors Care?,2016-12-05 12:16:00-05:00,BLUE,positive
172727.0,bluebird bio Presents New Data from HGB-205 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent ,2016-12-03 15:27:00-05:00,BLUE,neutral
172728.0,bluebird bio Names Susanna High COO,2016-12-02 08:00:00-05:00,BLUE,neutral
172729.0,"Bluebird News A Positive For Juno, Kite Pharma",2016-12-01 15:07:00-05:00,BLUE,positive
172730.0,"Bluebird 'Potentially The Walter White Of CAR T Therapy,' Says BTIG",2016-12-01 14:16:00-05:00,BLUE,neutral
172731.0,Analyst Breaks Down Bluebird Bio's Better-Than-Expected Clinical Results,2016-12-01 13:33:00-05:00,BLUE,neutral
172732.0,18 Biggest Mid-Day Gainers For Thursday,2016-12-01 12:45:00-05:00,BLUE,neutral
172733.0,Technical Alert: Bluebird Bio Soars After Encouraging Myeloma Data,2016-12-01 11:59:00-05:00,BLUE,positive
172734.0,Mid-Morning Market Update: Markets Mostly Higher; Dollar General Profit Misses Views,2016-12-01 10:10:00-05:00,BLUE,positive
172735.0,"Heat Biologics Cools Off, Bluebird Bio Heats Up",2016-12-01 09:54:00-05:00,BLUE,neutral
172736.0,22 Stocks Moving In Thursday's Pre-Market Session,2016-12-01 08:30:00-05:00,BLUE,neutral
172737.0,Bluebird's Encouraging Myeloma Data Not Enough For Cantor To Lift Its Sell Rating,2016-12-01 07:59:00-05:00,BLUE,positive
172738.0,Bluebird Bio Shares +22% After Hours Following Release of Positive Data on Relapsed/Refractory Multiple Myeloma Study,2016-11-30 18:26:00-05:00,BLUE,positive
172739.0,"UPDATE: 6 of 6 Patients In 2nd & 3rd bluebird Cohorts Achieved Objective Response, Overall Response Rate Is 78%; No Grarde 3 or 4 Cytokine Release Syndrome Or Neurotoxicity Observed",2016-11-30 17:29:00-05:00,BLUE,negative
172740.0,Adam Feuerstein @adamfeuerstein  Tweet: $BLUE $CELG T-Cell Therapy Eliminates Multiple Myeloma with Minimal Side Effects thestreet.com/story/13909407,2016-11-30 17:29:00-05:00,BLUE,neutral
172741.0,bluebird bio Announces Interim Phase 1 Dose Escalation Data for its Anti-BCMA CAR T Product Candidate in Patients with Relapsed/Refractory Multiple Myeloma,2016-11-30 17:27:00-05:00,BLUE,neutral
172742.0,Adam Feuerstein @adamfeuerstein  Tweet: $BLUE $CELG anti-BCMA CAR-T data will be out tonight at 6 pm ET. Just FYI.,2016-11-30 16:03:00-05:00,BLUE,positive
172743.0,"PiperJaffray Healthcare Conference Begins Today, Day 1 of 2; Presenters Include NantKwest, Ignyta, Gilead Sciences, DexCom, Incyte, bluebird bio",2016-11-29 08:53:00-05:00,BLUE,neutral
172744.0,Benzinga's Top Initiations,2016-11-11 09:34:00-05:00,BLUE,positive
172745.0,"BMO Capital Initiates Coverage On bluebird bio, Inc. - Common Stock at Market Perform, Announces $61.00",2016-11-11 04:30:00-05:00,BLUE,neutral
172746.0,BlueBird Bio Inc Lower After Q3 Report,2016-11-03 14:02:00-04:00,BLUE,negative
172747.0,Bluebird Abstracts From Data Presentation At American Society Of Hematology Mtg Now Available,2016-11-03 09:05:00-04:00,BLUE,neutral
172748.0,"Bluebird Bio Reports Q3 Loss/Share $2.07, Rev $1.552M vs $1.78M Est",2016-11-02 16:15:00-04:00,BLUE,neutral
172749.0,"bluebird bio Shares Spike Higher Off Session Lows, Off $55.50 Level; Stock Now Up 0.8%; BZ NOTE: Watch for Near-Term Profit Taking as Traders Passing Around Unconfirmed Takeover Chatter",2016-10-18 11:22:00-04:00,BLUE,positive
172750.0,15 Biggest Mid-Day Losers For Friday,2016-10-14 13:38:00-04:00,BLUE,negative
172751.0,Bluebird Bio Shares Down 10%; Cantor Downgrades Stock To Sell,2016-10-14 11:56:00-04:00,BLUE,positive
172752.0,Technical Alert: Bluebird Bio Wounded After Cantor Fitzgerald Downgrade,2016-10-14 11:20:00-04:00,BLUE,positive
172753.0,10 Biggest Price Target Changes For Friday,2016-10-14 10:24:00-04:00,BLUE,neutral
172754.0,Benzinga's Top Downgrades,2016-10-14 09:42:00-04:00,BLUE,positive
172755.0,Tailwinds Continue To Hold The Street's Gaze Toward Bluebird Bio Aloft,2016-10-14 09:39:00-04:00,BLUE,neutral
172756.0,Bluebird's Gene Therapy Is Firing On All Cylinders,2016-10-14 08:41:00-04:00,BLUE,negative
172757.0,18 Stocks Moving In Friday's Pre-Market Session,2016-10-14 08:37:00-04:00,BLUE,neutral
172758.0,Favorable FDA Pathway Should Keep Bluebird's Clinical Studies Flying Straight,2016-10-14 08:21:00-04:00,BLUE,positive
172759.0,"Cantor Fitzgerald Downgrades bluebird bio, Inc. - Common Stock to Sell",2016-10-14 07:46:00-04:00,BLUE,neutral
172760.0,"Exclusive: SunTrust Managing Director Discusses Bluebird Bio, A Leader In Gene Therapy",2016-10-13 09:51:00-04:00,BLUE,positive
172761.0,"bluebird bio Reports Presentation That Focuses On Potential Improvements, Updates To Protocol For HGB-206 Trial, and Regulatory Plans",2016-10-13 08:02:00-04:00,BLUE,positive
172762.0,"Jefferies Gene Editing/Gene Therapy Summit Commences Today With Presenters Including bluebird bio, Audentes Therapeutics, Spark Therapeutics, Sangamo Biosciences, And uniQure",2016-10-11 08:23:00-04:00,BLUE,positive
172763.0,"BZ NOTE: Recent Stength In bluebird May Be Due To Chatter That Company Canceled Out Of A Upcoming Conference, bluebird bio Spokesperson Confirms To Benzinga That They Are Attending Jefferies Gene Therapy Conference",2016-09-30 11:20:00-04:00,BLUE,positive
172764.0,"Maxim Raises Target On bluebird bio From $85 To $100, Maintains Buy Rating",2016-09-29 11:53:00-04:00,BLUE,neutral
172765.0,"bluebird bio, Medigene Announce Strategic T Cell Receptor (TCR) Alliance in Cancer Immunotherap; Medigene to Receive Upfront Payment of $15M",2016-09-29 04:12:00-04:00,BLUE,negative
172766.0,Roth Capital Assumes bluebird bio at Buy,2016-09-22 08:38:00-04:00,BLUE,neutral
172767.0,bluebird Reports LentiGlobin Investigational Gene Therapy for Transfusion-Dependent Beta-Thalassemia Accepted into European Medicines Agency's PRIME Program,2016-09-21 08:30:00-04:00,BLUE,positive
172768.0,15 Biggest Mid-Day Gainers For Thursday,2016-09-15 12:44:00-04:00,BLUE,neutral
172769.0,Benzinga's Volume Movers,2016-09-15 11:13:00-04:00,BLUE,neutral
172770.0,Adam Feuerstein Tweets: $BLUE on fire in September. I hear investor conference 1x1s have gone well.,2016-09-15 09:39:00-04:00,BLUE,negative
172771.0,"Goldman Sees Bluebird Bio Preparing For Flight (115% Upside), Adds To 'Conviction Buy' List",2016-09-15 09:03:00-04:00,BLUE,neutral
172772.0,15 Stocks Moving In Thursday's Pre-Market Session,2016-09-15 08:27:00-04:00,BLUE,neutral
172773.0,"Goldman Sachs Maintains Buy on bluebird bio, Maintains $135.00 PT, Added To Conviction Buy List",2016-09-15 06:31:00-04:00,BLUE,neutral
172774.0,"TheStreet's Adam Feuerstein Publishes 'Bluebird Improves its Gene Therapy, Removing an Investor Concern'",2016-09-08 10:41:00-04:00,BLUE,positive
172775.0,"Adam Feuerstein @adamfeuerstein Tweet: New, enhanced gene therapy manufacturing process under current IND. Wipes out one of Street's concerns. $BLUE",2016-09-08 08:22:00-04:00,BLUE,neutral
172776.0,bluebird bio Opens Phase 3 Study of LentiGlobin Drug Product in Patients with Transfusion-Dependent Beta-Thalassemia,2016-09-08 08:16:00-04:00,BLUE,neutral
172777.0,Goldman's 7 Favorite Biotech Ideas For 2016,2016-09-07 16:13:00-04:00,BLUE,positive
172778.0,Bluebird Heading Into 'Catalyst-Rich' Second Half Of The Year,2016-09-07 10:59:00-04:00,BLUE,neutral
172779.0,Clear Skies For Bluebird Bio To Enter A New Inflection Point,2016-08-18 09:28:00-04:00,BLUE,positive
172780.0,"bluebird bio Reports Q2 EPS $(1.59) vs. Est. $(1.44), Rev. $1.552M vs. Est. $2.2M",2016-08-03 17:22:00-04:00,BLUE,neutral
172781.0,These Biotechs Are Getting Crushed Following Juno's Cancer Drug Hold,2016-07-08 11:17:00-04:00,BLUE,negative
172782.0,BlueBid Bio Sells Off to Low of $45.08 on Juno Clinical Hold News,2016-07-07 16:08:00-04:00,BLUE,negative
172783.0,"Bluebird Bio Initiated Hold At Cantor Fitzgerald, Decides To Await Additional Data",2016-06-02 17:19:00-04:00,BLUE,positive
172784.0,"Cantor Fitzgerald Initiates Coverage on bluebird bio at Hold, Announces $42.00 PT",2016-06-02 16:19:00-04:00,BLUE,neutral
172785.0,"BTIG Comments On Bluebird Bio's Q1 Print, Highlights Future Catalysts",2016-05-05 15:07:00-04:00,BLUE,neutral
172786.0,"bluebird bio Reports Q1 EPS $(1.52) vs $(1.23) Est., Sales $1.499M vs $4M Est.",2016-05-04 18:08:00-04:00,BLUE,neutral
172787.0,Adam Feuerstein On Biotechs: 'I Have An Itchy Trigger Finger On Hypocrisy',2016-05-02 18:22:00-04:00,BLUE,negative
172788.0,Bluebird Bio's LentiD 'Hits The Mark',2016-04-21 08:00:00-04:00,BLUE,neutral
172789.0,Adam Feuerstein @adamfeuerstein Tweet: $BLUE spox tells me that ASGCT abstract on Lenti-D in CALD abstractsonline.com/pp8/#!/4077/pr… listing tachycardia as an SAE is incorrect. It was Gr1.,2016-04-20 13:36:00-04:00,BLUE,neutral
172790.0,bluebird bio To Present Interim Data On Phase 2 Starbeam Study To Evaluate Lenti-D,2016-04-20 09:49:00-04:00,BLUE,neutral
172791.0,bluebird bio to Present Immuno-Oncology and Gene Therapy Data at the ASGCT 19th Annual Meeting,2016-04-18 16:09:00-04:00,BLUE,neutral
172792.0,Goldman Is Buying: Bluebird Bio Off To 'Flying Start',2016-04-08 10:27:00-04:00,BLUE,neutral
172793.0,How One Analyst Is Playing The Biotech Rebound This Week,2016-04-07 15:45:00-04:00,BLUE,positive
172794.0,"The Market In 5 Minutes: Friday, March 4, 2016",2016-03-04 14:15:00-05:00,BLUE,neutral
172795.0,"Premarket Wells Fargo Said BLUE Lenti-D Data Validates Pipeline, PiperJaffray Called Daya 'very promising'",2016-03-04 09:59:00-05:00,BLUE,positive
172796.0,BlueBird Bio Spikes to High of $57.80 on Volume; May be Attributed to Positive Analyst Comments on  Lenti-D Data,2016-03-04 09:53:00-05:00,BLUE,positive
172797.0,Benzinga's Top Initiations,2016-03-01 10:04:00-05:00,BLUE,positive
172798.0,"BTIG Research Initiates Coverage on bluebird bio at Buy, Announces $72.00 PT",2016-03-01 04:17:00-05:00,BLUE,neutral
172799.0,Bluebird Bio CFO Jim DeTore to Leave,2016-02-25 16:06:00-05:00,BLUE,negative
172800.0,"BlueBird Bio Reports Q4 EPS $(1.29) Vs Est $(1.11), Sales $1.5M Vs Est $3.21M",2016-02-24 16:14:00-05:00,BLUE,neutral
172801.0,Bluebird Bio Gains 9% After Co. Begins New Phase 1 Study,2016-02-17 12:52:00-05:00,BLUE,positive
172802.0,bluebird bio Reports First Patient Has Been Treated with bb2121 in CRB-401 Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma,2016-02-17 08:03:00-05:00,BLUE,neutral
172803.0,Benzinga's Top Initiations,2016-02-03 09:45:00-05:00,BLUE,positive
172804.0,"Leerink Swann Initiates Coverage on bluebird bio at Outperform, Announces $67.00 PT",2016-02-03 08:04:00-05:00,BLUE,neutral
172805.0,Janney Capital Initiates Coverage on bluebird bio at Buy,2016-01-05 16:50:00-05:00,BLUE,neutral
172806.0,10 Biotechs Short Sellers Are Betting Against,2015-12-29 08:22:00-05:00,BLUE,neutral
172807.0,The Top 20 Wall Street Analysts Of 2015,2015-12-17 10:44:00-05:00,BLUE,positive
172808.0,Mid-Afternoon Market Update: Crude Oil Declines 6%; Bluebird Bio Shares Tumble,2015-12-07 14:45:00-05:00,BLUE,negative
172809.0,BlueBird Bio Unable To Rebound,2015-12-07 13:41:00-05:00,BLUE,neutral
172810.0,Notable Biotech Analyst Jason Napodano Says ASH Conference Stocks Poor Performance Today Are Due To Expectations Being Too High For The Stocks Right Now,2015-12-07 12:44:00-05:00,BLUE,negative
172811.0,Mid-Day Market Update: Dow Dips 150 Points; Sodastream Shares Spike Higher,2015-12-07 12:35:00-05:00,BLUE,positive
172812.0,Bluebuird Bio Crashes Nearly 30%: What's Next?,2015-12-07 10:53:00-05:00,BLUE,neutral
172813.0,Mid-Morning Market Update: Markets Open Lower; Keurig Green Mountain Agrees To Be Taken Private For $92/Share,2015-12-07 10:03:00-05:00,BLUE,negative
172814.0,Morning Market Losers,2015-12-07 09:53:00-05:00,BLUE,negative
172815.0,Benzinga's Top Downgrades,2015-12-07 09:22:00-05:00,BLUE,positive
172816.0,"Morgan Stanley Cuts bluebird bio, Slashes Price Target From $143 To $69",2015-12-07 09:08:00-05:00,BLUE,negative
172817.0,Benzinga's Top #PreMarket Losers,2015-12-07 08:28:00-05:00,BLUE,negative
172818.0,Bank of America Downgrades bluebird bio to Neutral,2015-12-07 07:57:00-05:00,BLUE,neutral
172819.0,BlueBird Bio Shares Fall 28% on Mixed Sickle Cell Data Results Presented at #ASH2015,2015-12-07 07:47:00-05:00,BLUE,positive
172820.0,"Roth Capital Downgrades bluebird bio to Neutral, Lowers PT to $62.00",2015-12-07 07:31:00-05:00,BLUE,negative
172821.0,"Wedbush on bluebird bio: 'Treatment Challenges Highlighted by Sickest Patients Likely Increase Time to LentiGlobin Approval'; Outperform Reiterated, Target Reduced from $165 to $117",2015-12-07 07:21:00-05:00,BLUE,positive
172822.0,"Key Changes To Morgan Stanley Analyst Model On bluebird bio Downgrade, Reasons For PT Slash From $143 To $69/Share",2015-12-07 07:17:00-05:00,BLUE,negative
172823.0,"Morgan Stanley Analyst Believe bluebird bio Ash Conf. Data Have Turned Favorable Risk/Reward Thesis Upside Down Due To Inability Of BB305 To Consitently Produce Enough Hb In Sickle Cell Patients, Removing Floor In Their Valuation",2015-12-07 07:12:00-05:00,BLUE,positive
172824.0,"Morgan Stanley Downgrades bluebird bio to Equal-weight, Lowers PT to $69.00",2015-12-07 04:58:00-05:00,BLUE,negative
172825.0,Bluebird Presenting Mixed Results from HGB-206 Studay Sunday at #ASH2015 -Adam F/The Street,2015-12-06 09:04:00-05:00,BLUE,neutral
172826.0,bluebird bio Reports New Beta-thalassemia Major Data from Northstar Study of LentiGlobin at #ASH2015,2015-12-05 10:31:00-05:00,BLUE,neutral
172827.0,Wells Fargo Initiates Coverage on bluebird bio at Outperform,2015-12-04 07:56:00-05:00,BLUE,positive
172828.0,"Roth Reinstates Coverage On Bluebird Bio, Sees Massive 50% Upside",2015-12-03 08:51:00-05:00,BLUE,neutral
172829.0,bluebird bio and ViroMed Enter into License Agreement for Novel Antibodies to Develop Chimeric Antigen Receptor T Cell Therapy,2015-12-03 08:01:00-05:00,BLUE,positive
172830.0,"Roth Capital Assumes bluebird bio at Buy, Announces $121.00 PT",2015-12-03 07:33:00-05:00,BLUE,neutral
172831.0,Goldman Sees 2016 'Flight To Quality' In These Biotech Stocks,2015-11-18 11:05:00-05:00,BLUE,neutral
172832.0,Mid-Morning Market Update: Markets Open Higher; Lowe's Tops Q3 Estimates,2015-11-18 09:58:00-05:00,BLUE,positive
172833.0,Morning Market Gainers,2015-11-18 09:42:00-05:00,BLUE,neutral
172834.0,Benzinga's Top #PreMarket Gainers,2015-11-18 08:08:00-05:00,BLUE,positive
172835.0,"Goldman Sachs Initiates Coverage on bluebird bio at Buy, Announces $165.00 PT",2015-11-18 06:45:00-05:00,BLUE,neutral
172836.0,Wedbush's David Nierengarten Says bluebird bio's ASH Results Bode Well For Anti-BCMA Candidate bb2121,2015-11-16 11:23:00-05:00,BLUE,positive
172837.0,"UPDATE: Wedbush's Nierengarten Sees Results from NCI-Sponsored Study of Anti-BCMA CAR-T Cells Boding Well for bluebird bio's bb2121, Expected to Enter Clinic in '16",2015-11-16 11:22:00-05:00,BLUE,positive
172838.0,Wedbush's Nierengarten on ASH Late-Breaker Related to BCMA CAR-T Therapy Showing Anti-Myeloma Activity: Says Sees Read Through to bluebird bio,2015-11-16 11:21:00-05:00,BLUE,neutral
172839.0,Cooperman's Omega Liquidates Position in bluebird bio,2015-11-16 09:35:00-05:00,BLUE,neutral
172840.0,"Bluebird Bio Selling 'An Overreaction,' Data Is 'Fantastic' Says Biotech Expert",2015-11-05 10:24:00-05:00,BLUE,neutral
172841.0,bluebird bio Shares Down 15% With Release Of ASH Abstract This Morning,2015-11-05 09:21:00-05:00,BLUE,positive
172842.0,"UPDATE: Napodano Still Sees a 'Big Market Opportunity' for bluebird bio, 'and with the stock down 60% off the highs, I think priced in.'",2015-11-05 09:15:00-05:00,BLUE,positive
172843.0,"UPDATE: Napodano on bluebird bio: 'the awe of a universal cure is gone, and that perception is hurting the stock'",2015-11-05 09:14:00-05:00,BLUE,negative
172844.0,"Noted Biotech Analyst Jason Napodano Says bluebird bio Sell Off ""Looks Like An Overreaction, SCD Data & Data In non-BO/BO Patient Looks Fantastic""",2015-11-05 09:11:00-05:00,BLUE,positive
172845.0,Andy Biotech Tweets: #ASH15 Abstracts. Tweet Has Links To Each Biotech Company's Abstract,2015-11-05 09:09:00-05:00,BLUE,neutral
172846.0,BZ NOTE: Watch Biotech Stocks As ASH Conference Abstracts To Be Released At 9pm ET,2015-11-05 08:30:00-05:00,BLUE,positive
172847.0,"bluebird bio Reports Q3 Loss $1.18 vs Est Loss $0.94, Sales $1.32M Vs Est $5.21M",2015-11-04 16:12:00-05:00,BLUE,negative
172848.0,"Oppenheimer's Marai Mentions That Cellectis SA Run May Have Triggered ""ASH Trades"" Like bluebird bio Which Is Up 10.45% On The Day",2015-11-03 14:59:00-05:00,BLUE,positive
172849.0,"Wedbush's Nierengarten on bluebird bio: Sees Volatility Around ASH Meeting, 'But Shares Are Discounting Too Much'; Analyst Reiterates Outperform, $222 Target",2015-10-21 15:28:00-04:00,BLUE,positive
172850.0,Benzinga's Top Initiations,2015-10-20 09:23:00-04:00,BLUE,positive
172851.0,"Oppenheimer Initiates Coverage on bluebird bio at Outperform, Announces $162.00 PT",2015-10-20 07:54:00-04:00,BLUE,neutral
172852.0,Here's Why Biotechs Fell On Monday,2015-10-19 16:29:00-04:00,BLUE,neutral
172853.0,"Roth Capital Defending Bluebird Bio, Says They Are Buyers Into ASH Meeting, Says Co. Is Well Positioned To Leverage Robust In-House Expertise In Gene Editing And Lentiviral Vectorology",2015-10-19 14:11:00-04:00,BLUE,positive
172854.0,"Hearing JP Morgan Defending Bluebird Bio, Says Sell-Off Is Over-Reaction",2015-10-19 13:40:00-04:00,BLUE,positive
172855.0,"BlueBird Bio Shares Continue To Sell Off, Down Over 15% now",2015-10-19 12:56:00-04:00,BLUE,positive
172856.0,"Shares Of bluebirdbio Resume Trading, Now At $82.61/Share And Spiking Higher",2015-10-19 12:34:00-04:00,BLUE,positive
172858.0,"Bluebird Bio Resumes Trading, Rebounding A Bit From Pre-Halt Sell Off, Currently Trading $82.39",2015-10-19 12:27:00-04:00,BLUE,neutral
172859.0,BlueBird Bio Update On LG001 Study,2015-10-19 12:22:00-04:00,BLUE,neutral
172860.0,bluebirdbio Trading Halted,2015-10-19 12:22:00-04:00,BLUE,neutral
172861.0,bluebird bio Announces Presentation at Cooley's Anemia Foundation Symposium,2015-10-19 12:21:00-04:00,BLUE,neutral
172862.0,bluebird bio Shares Selloff as Company Announces Presentation at Cooley's Anemia Foundation Symposium,2015-10-19 12:20:00-04:00,BLUE,positive
172863.0,BlueBird Bio Shares Selling Off,2015-10-19 12:20:00-04:00,BLUE,positive
172864.0,bluebirdbio Shares Falling To $81.21/Share,2015-10-19 12:20:00-04:00,BLUE,positive
172865.0,Bluebird Bio Spikes to High,2015-10-13 11:09:00-04:00,BLUE,neutral
172866.0,Bluebird Bio Upgraded At Morgan Stanley; Firm Sees 'Innovation At A Discount',2015-10-05 09:07:00-04:00,BLUE,positive
172867.0,Benzinga's Top Upgrades,2015-10-05 09:06:00-04:00,BLUE,positive
172868.0,"UPDATE: Morgan Stanley Upgrades bluebird bio, Sees 'Innovation at a Discount'",2015-10-05 07:41:00-04:00,BLUE,positive
172869.0,Morgan Stanley Upgrades bluebird bio to Overweight,2015-10-05 02:30:00-04:00,BLUE,negative
172870.0,"Cramer Gives His Opinion On bluebird bio, Atmel And Time Warner Cable",2015-09-22 06:42:00-04:00,BLUE,neutral
172871.0,BlueBird Bio Spikes to High,2015-09-11 14:47:00-04:00,BLUE,neutral
172872.0,"Benzinga's M&A Chatter for Tuesday September 8, 2015",2015-09-08 21:02:00-04:00,BLUE,neutral
172873.0,"Hearing Dealreporter Chatter On Bluebio Takeover, Says To Be Acquired By Big Pharma For $300/Share - UNCONFIRMED",2015-09-08 09:40:00-04:00,BLUE,negative
172874.0,Benzinga's Top Initiations,2015-09-08 09:29:00-04:00,BLUE,positive
172875.0,"Morgan Stanley Initiates Coverage on bluebird bio at Equal-weight, Announces $143.00 PT",2015-09-08 04:19:00-04:00,BLUE,neutral
172876.0,What Should Biotech Investors Do Now?,2015-08-25 14:47:00-04:00,BLUE,neutral
172877.0,Market Panic Has Created 'Compelling' Opportunities In Biotech,2015-08-25 13:06:00-04:00,BLUE,positive
172878.0,"Roth Capital Believes 'Panic Has Created Some Compelling Opportunities on the Long Side' in Biotech; Highlights bluebird bio, Cempra, MacroGenics, Sarepta, uniQure, Nektar, PTC Therapeutics",2015-08-25 09:13:00-04:00,BLUE,positive
172879.0,Why Have Shares Of Global Blood Therapeutics Skyrocketed Since Its Debut?,2015-08-16 11:49:00-04:00,BLUE,positive
172880.0,Roth Capital Recommending Buying the Weakness in bluebird bio,2015-08-12 12:35:00-04:00,BLUE,negative
172881.0,bluebird Bio CEO Sells 125K Shares As Of August 7,2015-08-11 15:15:00-04:00,BLUE,positive
172882.0,Roth Says Buy The Dip In This Biotech,2015-08-07 09:47:00-04:00,BLUE,neutral
172883.0,"Roth Capital's Chattopadhyay Sees ~6% Decline in bluebird bio Shares as Offering an Attractive Entry Point; Buy Rating, $192 Target Maintained",2015-08-07 07:49:00-04:00,BLUE,positive
172884.0,"bluebird Bio Reports Q2 Loss $1.57 Vs Est Loss $0.79, Sales $4.940M Vs Est $8.61M",2015-08-06 16:47:00-04:00,BLUE,negative
172885.0,Roth Capital: Buy The Dips In Bluebird Bio,2015-07-13 14:55:00-04:00,BLUE,neutral
172886.0,Baillie Gifford Reports 10.34% Passive Stake in Bluebird Bio as of June 30,2015-07-07 10:24:00-04:00,BLUE,positive
172887.0,Kite Pharma CEO: 'We Are Offering The Next Generation Immunotherapy',2015-06-24 14:14:00-04:00,BLUE,neutral
172888.0,Kite Pharma Shares Its Vision: Here's How Wall Street Is Reacting,2015-06-24 12:15:00-04:00,BLUE,positive
172889.0,bluebird bio Prices ~2.941M Share Offering @$170.00/Share,2015-06-24 04:32:00-04:00,BLUE,positive
172890.0,UPDATE: Hearing 2.3M Share Offering in bluebird bio,2015-06-23 20:45:00-04:00,BLUE,positive
172891.0,bluebird bio Announces $400M Offering,2015-06-23 16:01:00-04:00,BLUE,neutral
172892.0,Kite Pharma and bluebird bio Announce Strategic Collaboration to Advance Second Generation TCR Cell Therapy Products to Treat HPV-Associated Cancers,2015-06-22 08:01:00-04:00,BLUE,positive
172893.0,Bluebird Bio's Positive LentiGlobin Data: Wall Street Responds,2015-06-15 11:35:00-04:00,BLUE,positive
172894.0,BMO Capital Raises Target on bluebird bio from $200 to $239.00,2015-06-15 10:09:00-04:00,BLUE,neutral
172895.0,Morning Market Gainers,2015-06-15 09:43:00-04:00,BLUE,neutral
172896.0,"UPDATE: Cowen Analyst on bluebird bio 'Optimistic Lenti-D, LentiGlobin Will Represent Meaningful Advances in Areas of High Unmet Need'",2015-06-15 08:15:00-04:00,BLUE,positive
172897.0,Benzinga's Top #PreMarket Gainers,2015-06-15 08:15:00-04:00,BLUE,positive
172898.0,Cowen On Bluebird Bio Says 'we gain some reassurance from teh favorable efficacy and saftey updates on BB305',2015-06-15 08:14:00-04:00,BLUE,positive
172899.0,"Suntrust Maintains Buy on bluebird bio, Raises PT to $230.00",2015-06-15 07:40:00-04:00,BLUE,neutral
172900.0,"Philip Gregory, D. Phil., Joins bluebird bio as Chief Scientific Officer",2015-06-15 07:32:00-04:00,BLUE,neutral
172901.0,"JP Morgan Maintains Overweight on bluebird bio, Raises PT to $244.00",2015-06-15 07:26:00-04:00,BLUE,neutral
172902.0,bluebird bio Presents New Beta-thalassemia Major and Severe Sickle Cell Disease Data from HGB-205 Study at EHA,2015-06-13 07:56:00-04:00,BLUE,negative
172903.0,Bluebird Bio Shares Under Pressure As Wedbush Warns Of Pediatric Study Delay,2015-06-10 12:15:00-04:00,BLUE,negative
172904.0,"bluebird bio Shares Down 2.5% Premarket as Wedbush Note Highlighting NIH Advisory Panel Has Recommended Delaying Pediatric Study Initiation, But Says Does Not Impact FDA",2015-06-10 08:48:00-04:00,BLUE,positive
172905.0,Benzinga's Top #PreMarket Losers,2015-06-10 08:17:00-04:00,BLUE,negative
172906.0,What Does The Russell Reconstitution Mean For You?,2015-06-05 16:50:00-04:00,BLUE,neutral
172907.0,"Jim Cramer Shares His Thoughts On L Brands, Revance Therapeutics And bluebird bio",2015-06-05 07:23:00-04:00,BLUE,positive
172908.0,Analysts Weigh In On Amended Bluebird Bio/Celgene Deal,2015-06-04 11:53:00-04:00,BLUE,neutral
172909.0,"8-K from bluebird bio on Celgene Deal Shows Co. 'will be eligible to receive up to $10.0 million in clinical milestone payments, up to $117.0 million in regulatory milestone payments and up to $78.0 million in commercial milestone payments.'",2015-06-03 16:19:00-04:00,BLUE,neutral
172910.0,"Celgene, bluebird bio To Develop Anti-BCMA Product Candidates; bluebird bio Regains Rights to CAR T Programs Outside of BCMA",2015-06-03 16:02:00-04:00,BLUE,neutral
172911.0,"BMO Capital: Five Prime Therapeutics Still A Buy, Worth $31/Share Now",2015-05-28 09:35:00-04:00,BLUE,positive
172912.0,Morning Market Gainers,2015-05-27 09:44:00-04:00,BLUE,neutral
172913.0,Benzinga's Top #PreMarket Gainers,2015-05-27 08:11:00-04:00,BLUE,positive
172914.0,Five Prime Therapeutics Shares Rise 17% After-Hours Following Announcement of Deal With Bluebird Bio,2015-05-26 16:10:00-04:00,BLUE,positive
172915.0,"bluebird bio, Five Prime Therapeutics Enter Exclusive License Agreement For Novel Antibodies To Develop Chimeric Antigen Receptor T Cell Therapy",2015-05-26 16:07:00-04:00,BLUE,positive
172916.0,"Bluebird Bio Now Worth $213/Share, Piper Jaffray Says",2015-05-26 10:21:00-04:00,BLUE,positive
172917.0,BlueBird Bio: Another Biogen Rout In The Making?,2015-05-21 14:20:00-04:00,BLUE,neutral
172918.0,Morning Market Gainers,2015-05-21 09:49:00-04:00,BLUE,neutral
172919.0,Benzinga's Top #PreMarket Gainers,2015-05-21 08:08:00-04:00,BLUE,positive
172920.0,bluebird bio to Present LentiGlobin Clinical Data at 20th Congress of European Hematology Association,2015-05-21 07:12:00-04:00,BLUE,neutral
172921.0,Wedbush Sees More News On Bluebird Bio Coming Thursday,2015-05-20 08:35:00-04:00,BLUE,neutral
172922.0,"BlueBird Bio Drug Might Get Accelerated OK In U.S., Europe",2015-05-19 14:31:00-04:00,BLUE,positive
172923.0,BlueBird Bio Soars Off Potential Drug Approval,2015-05-19 13:50:00-04:00,BLUE,positive
172924.0,"JP Morgan Reiterates On Bluebird Bio, Says It's 'Still Streaking'",2015-05-19 10:09:00-04:00,BLUE,positive
172925.0,"bluebird bio Meets With EU, US Regulatory Authorities to Discuss Potential Approval Pathways for LentiGlobin BB305",2015-05-19 06:08:00-04:00,BLUE,positive
172926.0,SunTrust: Bluebird Bio Might Fly On Sickle Cell Results,2015-05-11 13:50:00-04:00,BLUE,neutral
172927.0,bluebird bio Reports Q1 Loss of $0.76/Share vs Loss of $0.61/Share Est.,2015-05-06 16:32:00-04:00,BLUE,negative
172928.0,Biogen Or Bluebird: Which Will Lead In SCD?,2015-04-30 12:42:00-04:00,BLUE,neutral
172929.0,"Piper Jaffray Maintains Overweight on bluebird bio, Raises PT to $186.00",2015-04-29 06:40:00-04:00,BLUE,negative
172930.0,Adam Feuerstein @adamfeuerstein Tweet: From last night --> Gene Therapy Stocks on Watch Following Failure of $CLDN Heart Failure Trial thestreet.com/story/13126476… $BLUE $QURE $ONCE,2015-04-27 06:37:00-04:00,BLUE,negative
172931.0,"BMO Capital Initiates Coverage on bluebird bio at Outperform, Announces $160.00 PT",2015-04-22 17:24:00-04:00,BLUE,neutral
172932.0,Maxim Is Going Long Bluebird Bio,2015-04-22 08:47:00-04:00,BLUE,neutral
172933.0,Expert: Bluebird Bio Is 'One Of The Better Stories In Biotech',2015-04-17 15:03:00-04:00,BLUE,positive
172934.0,16 Biotech Catalysts SunTrust Is Tracking,2015-04-06 19:38:00-04:00,BLUE,neutral
172935.0,Bluebird Bio: Here's Why Wedbush Is Bullish,2015-02-26 17:44:00-05:00,BLUE,neutral
172936.0,These Analysts See Upside At Continental Resources,2015-02-26 17:20:00-05:00,BLUE,neutral
172937.0,Bluebird Bio Ticks Down On Wider Loss,2015-02-25 18:06:00-05:00,BLUE,negative
172938.0,"bluebird bio Reports Q4 EPS -$0.67 Vs Est -$0.57, Sales $6.39M Vs Est $6.18M",2015-02-25 16:25:00-05:00,BLUE,neutral
172939.0,Wedbush Weighs In On Medivation Following Phase II TERRAIN Study Results,2015-02-03 11:01:00-05:00,BLUE,neutral
172940.0,Mid-Day Market Update: U.S. Stocks Turn Higher; Tenneco Shares Rise On Upbeat Earnings,2015-02-02 12:23:00-05:00,BLUE,positive
172941.0,Mid-Morning Market Update: Markets Tumble; Exxon Mobil Profit Beats Views,2015-02-02 10:34:00-05:00,BLUE,positive
172942.0,Morning Market Gainers,2015-02-02 09:44:00-05:00,BLUE,neutral
172943.0,Bluebird Bio Surges Following FDA Decision,2015-02-02 09:43:00-05:00,BLUE,neutral
172944.0,Benzinga's Top #PreMarket Gainers,2015-02-02 08:17:00-05:00,BLUE,positive
172945.0,Blubird Bio Shares Rise 10% Premarket Following Announcement of FDA Breakthrough Therapy Designation for LentiGlobin,2015-02-02 07:55:00-05:00,BLUE,positive
172946.0,UPDATE: Blubird Bio Announces FDA Breakthrough Therapy Designation for LentiGlobin,2015-02-02 07:05:00-05:00,BLUE,neutral
172947.0,Adam Feuerstein @adamfeuerstein Tweet: $BLUE receives FDA breakthrough therapy designation for Lentiglobin in beta thalassemia.,2015-02-02 07:02:00-05:00,BLUE,neutral
172948.0,"bluebird bio Announces Transition of Chief Scientific Officer Mitchell H. Finer, Ph.D.",2015-01-29 16:23:00-05:00,BLUE,neutral
172949.0,bluebird bio Names Mitchell Finer Chief Scientific Officer,2015-01-29 16:07:00-05:00,BLUE,neutral
172950.0,UPDATE: BlueBird Bio Shares Spike Higher; Hearing Wedbush Raises PT from $94 to $146,2015-01-21 12:21:00-05:00,BLUE,positive
172951.0,BlueBird Bio Spikes Higher,2015-01-21 12:19:00-05:00,BLUE,neutral
172952.0,Why Drug Pricing Could Bring Volatility To The Biotech Sector This Year,2015-01-20 16:21:00-05:00,BLUE,neutral
172953.0,10 Biotech Stories You Might've Missed This Week,2015-01-15 13:18:00-05:00,BLUE,negative
172954.0,Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 3,2015-01-13 10:58:00-05:00,BLUE,neutral
172955.0,Wall Street's Hall Of Fame (And Hall Of Shame): The Best And Worst Analyst Recommendations Of 2014,2015-01-12 08:42:00-05:00,BLUE,positive
172956.0,The Top 5 Biotech Gainers Of 2014,2014-12-29 14:15:00-05:00,BLUE,positive
172957.0,"Roth Capital Maintains Buy on bluebird bio, Raises PT to $120.00",2014-12-29 11:42:00-05:00,BLUE,neutral
172958.0,bluebird bio Prices 2.65M Share Offering @$85.00/Share,2014-12-15 21:51:00-05:00,BLUE,positive
172959.0,UPDATE: Wedbush Reiterates On bluebird bio On Updated Data,2014-12-10 09:51:00-05:00,BLUE,neutral
172960.0,Mid-Morning Market Update: Markets Open Lower; AutoZone Posts Upbeat Results,2014-12-09 11:27:00-05:00,BLUE,negative
172961.0,Benzinga's Volume Movers,2014-12-09 10:14:00-05:00,BLUE,neutral
172962.0,Stocks Hitting 52-Week Highs,2014-12-09 10:00:00-05:00,BLUE,neutral
172963.0,Morning Market Movers,2014-12-09 09:40:00-05:00,BLUE,neutral
172964.0,bluebird bio Inc Shares Up Sharply Following Positive Drug Data,2014-12-09 08:44:00-05:00,BLUE,positive
172965.0,Benzinga's Top #PreMarket Gainers,2014-12-09 08:13:00-05:00,BLUE,positive
172966.0,UPDATE: Bluebird Bio Shares Rise 61% Premarket on Positive Lentiglobin Bb305 Results,2014-12-09 07:25:00-05:00,BLUE,positive
172967.0,"Wedbush Reiterates Outperform on bluebird bio, Raises PT to $94.00",2014-12-09 06:11:00-05:00,BLUE,neutral
172968.0,UPDATE: Bluebird Bio Shares Now Up 56% After-Hours on Positive Lentiglobin Bb305 Data,2014-12-08 19:12:00-05:00,BLUE,positive
172969.0,UPDATE: Bluebird Bio Shares Now Up 35% After-Hours on Positive Lentiglobin Bb305 Data,2014-12-08 18:37:00-05:00,BLUE,positive
172970.0,bluebird bio Reports First Four Patients with β-Thalassemia Major Treated with LentiGlobin are Transfusion-Free,2014-12-08 17:53:00-05:00,BLUE,neutral
172971.0,Bluebird Bio Shares Rise 25% After-Hours on Positive Data from Eight Subjects Treated With Lentiglobin Bb305,2014-12-08 17:52:00-05:00,BLUE,positive
172972.0,Ian Estepan ‏@ianestepan  Tweet: $BLUE sounds quite bullish at Piper - they obviously know the data at ASH - people will be upset if the data underwhelms...,2014-12-02 15:40:00-05:00,BLUE,negative
172973.0,James M. DeTore Joins Bluebird Bio As CFO,2014-11-10 07:01:00-05:00,BLUE,neutral
172974.0,"Bluebird Bio Ceo Leschly Sells 8,000 Shares @$34.55/Share -Form 4",2014-10-03 08:17:00-04:00,BLUE,positive
172975.0,"Roth Capital Initiates Coverage on bluebird bio at Buy, Announces $50.00 PT",2014-09-22 05:41:00-04:00,BLUE,neutral
172976.0,"Adam Feuerstein @adamfeuerstein Tweet: $BLUE spox to me: ""We're dosing [sickle cell patients] by end of year. We'll have clinically meaningful data in 2015.""",2014-09-16 12:54:00-04:00,BLUE,positive
172977.0,"SunTrust Robinson Humphrey Initiates Coverage on bluebird bio at Buy, Announces $57.00 PT",2014-09-04 16:38:00-04:00,BLUE,neutral
172978.0,Top 5 Performing Biotech Stocks Of 2014,2014-09-03 12:08:00-04:00,BLUE,positive
172979.0,bluebird bio Reports Q2 EPS of $(0.06) vs $(0.45) Est; Revenue of $6.30M vs $6.15M Est,2014-08-12 16:18:00-04:00,BLUE,neutral
172980.0,2 Biotech Stocks With Massive Increases In Short Interest,2014-07-28 16:30:00-04:00,BLUE,positive
172981.0,Bluebird Bio Shares Move Higher; May be Attributed to Positive Street.com Article ,2014-07-17 10:47:00-04:00,BLUE,positive
172982.0,Bluebird Prices 3M Share Offering at $34/Share,2014-07-08 19:06:00-04:00,BLUE,positive
172983.0,bluebird bio Announces Proposed Offering of $100M in Shares,2014-07-07 16:02:00-04:00,BLUE,positive
172984.0,Filing from Bluebird Bio Shows Registration for Automatic Mixed Securities Shelf,2014-07-02 08:58:00-04:00,BLUE,positive
172985.0,Blubird Bio Announces Acquisition of Precision Genome Engineering For ~408k Shares of Stock and Paid or Assumed $4.9M Of Liabilities,2014-06-30 16:09:00-04:00,BLUE,positive
172986.0,"Adam Feuerstein Likes Zafgen, Bluebird Bio",2014-06-20 08:33:00-04:00,BLUE,positive
172987.0,Mid-Afternoon Market Update: US Stocks Reverse Earlier Loses; Fusion-io Shares Jump On SanDisk Buyout,2014-06-16 15:03:00-04:00,BLUE,neutral
172988.0,"Mid-Day Market Movers For Monday, June 16, 2014",2014-06-16 12:52:00-04:00,BLUE,neutral
172989.0,Mid-Day Market Update: US Stocks Turn Red; Fusion-IO Shares Jump On SanDisk Buyout,2014-06-16 12:23:00-04:00,BLUE,positive
172990.0,Benzinga's Volume Movers,2014-06-16 10:26:00-04:00,BLUE,neutral
172991.0,​Mid-Morning Market Update: Markets Mostly Higher; Medtronic To Acquire Covidien For $42.9B,2014-06-16 10:24:00-04:00,BLUE,neutral
172992.0,Stocks Hitting 52-Week Highs,2014-06-16 10:14:00-04:00,BLUE,neutral
172993.0,Morning Market Movers ,2014-06-16 09:40:00-04:00,BLUE,neutral
172994.0,Benzinga's Top #PreMarket Gainers,2014-06-16 08:08:00-04:00,BLUE,positive
172995.0,"bluebird bio Shares Rise 53% in Premarket, Following Presentation of Positive Data on LentiGlobin BB305 at EHA",2014-06-16 07:05:00-04:00,BLUE,positive
172996.0,bluebird bio Presents Positive Data on LentiGlobin BB305 at EHA,2014-06-14 17:11:00-04:00,BLUE,positive
172997.0,Top 4 NASDAQ Stocks In The Biotechnology Industry With The Highest EPS,2014-05-09 04:48:00-04:00,BLUE,positive
172998.0,5 Healthcare Stocks With The Highest EPS,2014-04-01 09:55:00-04:00,BLUE,neutral
172999.0,bluebird bio Reports FY EPS of $(2.02) vs $(1.52) Est; Revenue of $20.20M vs $20.18M Est,2014-03-05 16:33:00-05:00,BLUE,neutral
173000.0,"Bluebird Bio Announces First Patient Transplanted in Phase 1/2 HGB-205 Beta-Thalassemia, Sickle Cell Anemia Study ",2013-12-02 06:47:00-05:00,BLUE,neutral
173001.0,Stocks Hitting 52-Week Lows,2013-11-18 10:23:00-05:00,BLUE,negative
173002.0,Stocks Hitting 52-Week Lows,2013-10-09 10:08:00-04:00,BLUE,negative
173003.0,bluebird bio Reports Q2 EPS of $(2.13) Which May Not Compare $(0.35) Est; Revenue of $6.30M Which May Not Compare $4.48M Est,2013-08-14 16:08:00-04:00,BLUE,neutral
173004.0,"Cowen & Company Initiates Coverage on bluebird bio at Outperform, Announces $44.00 PT",2013-07-30 09:15:00-04:00,BLUE,neutral
173005.0,"Bluebird Initiated at Wedbush with Outperform, $40 PT",2013-07-15 12:33:00-04:00,BLUE,neutral
173006.0,UPDATE: J.P. Morgan Initiates bluebird bio at Overweight on Unique & Necessary Medical Products,2013-07-15 08:55:00-04:00,BLUE,negative
173007.0,UPDATE: Canaccord Genuity Initiates bluebird bio at Buy on Strong Gene Therapy Platform,2013-07-15 08:45:00-04:00,BLUE,positive
173008.0,UPDATE: Bank of America Initiates bluebird bio at Buy on Transformational Potential,2013-07-15 08:26:00-04:00,BLUE,neutral
173009.0,Benzinga's Top Initiations,2013-07-15 07:43:00-04:00,BLUE,positive
173010.0,"JP Morgan Initiates Coverage on bluebird bio at Overweight, Announces $44.00 PT",2013-07-15 06:54:00-04:00,BLUE,neutral
173011.0,"Canaccord Genuity Initiates Coverage on bluebird bio at Buy, Announces $45.00 PT",2013-07-15 06:49:00-04:00,BLUE,neutral
173012.0,"Bank of America Initiates Coverage on bluebird bio at Buy, Announces $42.00 PO",2013-07-15 06:46:00-04:00,BLUE,negative
173013.0,Stocks Hitting 52-Week Lows,2013-06-28 10:26:00-04:00,BLUE,negative
173014.0,bluebird bio Announces Closing of Initial Public Offering and Exercise of Over-Allotment Option ,2013-06-24 16:07:00-04:00,BLUE,neutral
173015.0,Afternoon Market Gainers,2013-06-19 12:29:00-04:00,BLUE,neutral
173016.0,"Shares of bluebird bio Open for Trade at $25.50/Share, Priced at $17",2013-06-19 10:25:00-04:00,BLUE,positive
173017.0,"bluebird bio IPO to Open This Morning, Priced ~5.94M Shares at $17/Share, Initial Range Was $14-16",2013-06-19 09:09:00-04:00,BLUE,positive
